<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1390263</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Emerging role of immunogenic cell death in cancer immunotherapy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Arimoto</surname>
<given-names>Kei-ichiro</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2662404"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miyauchi</surname>
<given-names>Sayuri</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Mengdan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Dong-Er</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Moores Cancer Center, University of California San Diego</institution>, <addr-line>La Jolla, CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>School of Biological Sciences, University of California San Diego</institution>, <addr-line>La Jolla, CA</addr-line>, <country>United States</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Pathology, University of California San Diego</institution>, <addr-line>La Jolla, CA</addr-line>, <country>United States</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Oliver Kepp, INSERM U1138 Centre de Recherche des Cordeliers (CRC), France</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Shaoxian Wu, Soochow University, China</p>
<p>Rodwell Mabaera, Dartmouth Hitchcock Medical Center, United States</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Kei-ichiro Arimoto, <email xlink:href="mailto:karimoto@health.ucsd.edu">karimoto@health.ucsd.edu</email>; Dong-Er Zhang, <email xlink:href="mailto:d7zhang@health.ucsd.edu">d7zhang@health.ucsd.edu</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1390263</elocation-id>
<history>
<date date-type="received">
<day>23</day>
<month>02</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Arimoto, Miyauchi, Liu and Zhang</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Arimoto, Miyauchi, Liu and Zhang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Cancer immunotherapy, such as immune checkpoint blockade (ICB), has emerged as a groundbreaking approach for effective cancer treatment. Despite its considerable potential, clinical studies have indicated that the current response rate to cancer immunotherapy is suboptimal, primarily attributed to low immunogenicity in certain types of malignant tumors. Immunogenic cell death (ICD) represents a form of regulated cell death (RCD) capable of enhancing tumor immunogenicity and activating tumor-specific innate and adaptive immune responses in immunocompetent hosts. Therefore, gaining a deeper understanding of ICD and its evolution is crucial for developing more effective cancer therapeutic strategies. This review focuses exclusively on both historical and recent discoveries related to ICD modes and their mechanistic insights, particularly within the context of cancer immunotherapy. Our recent findings are also highlighted, revealing a mode of ICD induction facilitated by atypical interferon (IFN)-stimulated genes (ISGs), including polo-like kinase 2 (<italic>PLK2</italic>), during hyperactive type I IFN signaling. The review concludes by discussing the therapeutic potential of ICD, with special attention to its relevance in both preclinical and clinical settings within the field of cancer immunotherapy.</p>
</abstract>
<kwd-group>
<kwd>immunogenic cell death (ICD)</kwd>
<kwd>anti-tumor immune response</kwd>
<kwd>USP18 (UBP43)</kwd>
<kwd>PLK2</kwd>
<kwd>immunotherapies</kwd>
<kwd>tumor micreoenvironment (TME)</kwd>
<kwd>tumor biology</kwd>
<kwd>interferon</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="206"/>
<page-count count="15"/>
<word-count count="6969"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>To improve the efficacy of anti-cancer immunotherapies, numerous studies have concentrated on immune cells, exploring strategies to target the immunosuppressive tumor microenvironment (TME) such as T-cell suppressors and inhibitory immune checkpoints (<xref ref-type="bibr" rid="B1">1</xref>&#x2013;<xref ref-type="bibr" rid="B4">4</xref>). Indeed, some cancer patients derive clear benefits from these T-cell-based immunotherapies (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). However, unfortunately, most solid tumors are &#x201c;cold&#x201d; tumors with low immunogenicity (the ability of tumor antigen to trigger immune response), limited immune cell infiltration, and insufficient immunological responses. This results in poor responses by approaches that solely enhance T-cell function (<xref ref-type="bibr" rid="B7">7</xref>). Consequently, many oncologists have shifted their focus towards developing methods to transition cold tumors into &#x201c;hot&#x201d; tumors in combination with T-cell-based therapy, thereby augmenting intratumor immunogenicity. This process is commonly referred to as &#x2018;inflaming the TME&#x2019; (<xref ref-type="bibr" rid="B8">8</xref>). To inflame the TME favorably for anti-tumor immunity, various approaches, such as oncolytic viruses, have been proposed (<xref ref-type="bibr" rid="B9">9</xref>). Among these, the induction of immunogenic cell death (ICD) in tumors has garnered significant interest (<xref ref-type="bibr" rid="B10">10</xref>&#x2013;<xref ref-type="bibr" rid="B12">12</xref>).</p>
</sec>
<sec id="s2">
<title>Features of ICD</title>
<p>ICD, discovered by Guido Kroemer&#x2019;s group in 2005 (<xref ref-type="bibr" rid="B13">13</xref>&#x2013;<xref ref-type="bibr" rid="B15">15</xref>), is a form of cell death that activates the immune system, initiating an inflammatory response and facilitating the recognition of dying cells by the immune system (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). This feature is pivotal in contrast to non-immunogenic cell death, such as canonical apoptosis, where the immune system remains unaffected or may even be suppressed (e.g., by the expression of Transforming Growth Factor-&#x3b2; (TGF-&#x3b2;)). ICD is characterized by the release or cell-surface expression of highly immunostimulatory damage-associated molecular patterns (DAMPs) from dying tumor cells with ruptured cell membranes, followed by the induction of the innate and adaptive tumor-specific immune responses. The extracellular release of the nuclear protein high mobility group box 1 (HMGB1) and adenosine triphosphate (ATP), both termed as &#x2018;alarmins,&#x2019; acts as an attractant and activates antigen-presenting cells (APCs), such as dendritic cells (DCs). Extracellular HMGB1 binds to the receptors (e.g., Toll-like receptor 2 (TLR2), TLR4, and RAGE (receptors for advanced glycation end-products)) of immature DCs which cause DC maturation and cytotoxic T lymphocytes (CTLs) activation (<xref ref-type="bibr" rid="B16">16</xref>). Extracellular ATP acts as a powerful chemotactic agent for APCs and their precursors by binding to purinergic receptors P2Y2R and P2X7R to promote interleukin 1&#x3b2; (IL-1&#x3b2;) and IFN-&#x3b3; expression and CD8<sup>+</sup> T-cell priming (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Simultaneously, the display of calreticulin (CRT), normally residing inside the endoplasmic reticulum but translocated to the dying cell&#x2019;s surface, serves as an &#x201c;eat-me&#x201d; signal for phagocytes like macrophages (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B19">19</xref>&#x2013;<xref ref-type="bibr" rid="B22">22</xref>). The immunogenicity of CRT expressing cells could be effectively abolished by CRT inhibition with blocking antibodies, or by CRT knockdown with specific small interfering RNAs (<xref ref-type="bibr" rid="B21">21</xref>). Conversely, mRNA expression of CRT in cancer cells affects the composition and density of infiltrating immune cells (<xref ref-type="bibr" rid="B23">23</xref>). Indeed, CRT expression is mainly linked to CTLs and DCs infiltration in various types of cancer, such as colorectal, ovarian, and breast cancers. The membrane expression of heat shock proteins, such as HSP70 and HSP90 during ICD, also contributes to immune stimulation (<xref ref-type="bibr" rid="B24">24</xref>). Both HSP70 and HSP90 is usually located in the intracellular compartment, however, these HSPs translocate to cell surface during ICD. These ecto-HSP70 and HSP90 can interact with receptors on the surface APCs (e.g., CD40 and CD91) and enhance the immunogenicity of dying cells, results in the cross-presentation of cancer cell antigens to major histocompatibility complex (MHC)-I molecules and subsequent activation of CD8<sup>+</sup>&#x2009;T-cells (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>). Antigens from dying cancer cells are taken up and processed by APCs, which then present these antigens through their MHC-I molecules to T cells (<xref ref-type="bibr" rid="B27">27</xref>). Above mentioned DAMPs are called constitutive DAMPs (cDAMPs) and critically important to initiate ICD-mediated anti-tumor immunity (<xref ref-type="bibr" rid="B8">8</xref>). In addition to DAMPs, pathogen-associated molecular patterns (PAMPs), including endogenous RNA and double-stranded DNA (dsDNA) (endogenous and exogenous if oncolytic virus-mediated ICD), can also be released during ICD. PAMP sensors are responsible for the release of type I IFNs and C-X-C motif chemokine ligand 10 (CXCL10) through IRF3 and NF-&#x3ba;B pathways (<xref ref-type="bibr" rid="B28">28</xref>&#x2013;<xref ref-type="bibr" rid="B31">31</xref>). Absent in melanoma 2 (AIM2) inflammasome can sense dsDNA released by ICD cells, thereby inducing IL-1&#x3b2; secretion (<xref ref-type="bibr" rid="B32">32</xref>). These cytokines have been implicated in DC maturation, T, and natural killer (NK) cell recruitment. Type I IFNs enhance the cytotoxicity of CTLs and NK cells and promote the cross-presentation of DCs (<xref ref-type="bibr" rid="B33">33</xref>, <xref ref-type="bibr" rid="B34">34</xref>). These cytokines and chemokines are transcriptionally induced therefore called inducible DAMPs (iDAMPs) (<xref ref-type="bibr" rid="B8">8</xref>). As such, tumor cells undergoing ICD act as an endogenous vaccine, attracting activated immune cells into the tumor microenvironment or draining lymph node.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Illustration of the mechanism of cancer immunogenic cell death (ICD) and the subsequent activation of the antitumor immune response. Dying cancer cells express various constitutive damage-associated molecular patterns (cDAMPs) and inducible DAMPs, including the release of high mobility group box 1 (HMGB1) from the nucleus, translocation and cell surface exposure of calreticulin (ecto-CRT) and heat shock proteins HSP70/90, and extracellular secretion of ATP, cytokines (such as type I IFN), chemokines (such as CXCL10), and nucleic acids. Exposure to DAMPs serves as a &#x201c;find me&#x201d; signal which recruits immature dendritic cells (DC) to tumor microenvironment (TME) and induces the maturation of DC. Ecto-CRT provides a pro-phagocytic &#x201c;eat me&#x201d; signal that promotes the phagocytosis of antigens by DC. In addition, HMGB1 and HSP70/90 assist in promoting the processing of phagocytic cargo by binding to toll-like receptors (TLRs), thereby escalating antigen engulfment, processing, and cross-presentation to CD8<sup>+</sup> T cells to mediate robust tumor-specific immune response and protective immunological memory. Ecto-HSP70 and HSP90 also stimulate NK cell lysis. Primed CTLs elicit direct cytotoxic response and eradicate remaining tumor cells through the generation of IFN-&#x3b3;, perforin-1 and granzyme B.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1390263-g001.tif"/>
</fig>
<p>Importantly, various tumor-associated neo-antigens derived from cancer-specific somatic mutations or gene fusions should be present during ICD. Tumor-specific peptides displayed by APCs can activate T cells, particularly the activation of CTLs, which are then licensed to engage in tumor-specific immunity. This principle of ICD can be confirmed by a vaccination scenario known as the &#x2018;gold standard vaccination assay,&#x2019; where inoculation of mice with tumor cells killed by ICD induction prevents the subsequent growth of live tumor cells (<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>). Importantly, traditional cancer treatment regimens, such as chemotherapy and radiation, are related to ICD induction. While not all chemotherapeutic agents induce ICD, some, such as anthracyclines (e.g., Doxorubicin and mitoxantrone) and oxaliplatin, are known ICD inducers (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B37">37</xref>). In human breast and colorectal cancer patients treated with anthracyclines or oxaliplatin, favorable clinical outcomes were found to be associated with an increased number of cytotoxic CD8<sup>+</sup> T cells within the tumor (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). The loss of DC function was identified as a negative predictor of the therapeutic response to anthracyclines or oxaliplatin in both clinical and preclinical settings (<xref ref-type="bibr" rid="B40">40</xref>, <xref ref-type="bibr" rid="B41">41</xref>).</p>
</sec>
<sec id="s3">
<title>Evolution of ICD in cancer</title>
<p>Various types of cell death, such as apoptosis, necrosis, alkaliptosis, anoikis, autosis, autophagy, cuproptosis, disulfidptosis, entosis, erebosis, ferroptosis, lysosomal cell death (LCD), methuosis, mitoptosis, necroptosis, NETosis, oxeiptosis, paraptosis, parthanatos, pyroptosis, and immunogenic cell death (ICD), have been identified, exhibiting either caspase-dependent or -independent characteristics. While ICD is classified as one of the cell death modes, other modes may be considered ICD-like if their consequences align with the features of ICD, namely, the release of damage-associated molecular patterns (DAMPs) and the induction of the innate and adaptive immune responses. Notably, necroptosis, ferroptosis, and pyroptosis have been extensively studied and are regarded as forms of ICD, despite their distinct mechanisms (<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B43">43</xref>). In recent years, growing evidence suggests that some other modalities of cancer cell death also exhibit ICD features. In this review, we explore and discuss several modes of cancer cell death with ICD phenotypes, focusing particularly on recent reports within the field of cancer immunotherapy (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2</bold>
</xref>, <xref ref-type="fig" rid="f3">
<bold>3</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>A landscape of currently discovered ICD or ICD-like modes in cancer.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1390263-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Brief mechanistic description of current ICD or ICD-like modes in cancer. Necroptosis, ferroptosis, and pyroptosis have been extensively studied and are regarded as forms of ICD, despite their distinct mechanisms. Recent studies have started to reveal that other modes may be considered ICD-like if their consequences align with the features of ICD, namely, the release of damage-associated molecular patterns (DAMPs) and the induction of the innate and adaptive immune responses.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1390263-g003.tif"/>
</fig>
<sec id="s3_1">
<title>Necroptosis</title>
<p>Cell death is generally classified as accidental cell death (ACD) or regulated cell death (RCD), a genetically/molecularly controlled process. Necrotic cell death, a representative form of ACD, has long been considered a non-programmed and uncontrolled cell death. However, with research in over the past decade, we now understand that morphologically necrotic-like cell death is not only accidental but also programmed, referred to as &#x2018;necroptosis,&#x2019; and considered one of the modes of ICD (<xref ref-type="bibr" rid="B44">44</xref>). The necroptotic phenotype (controllable necrosis) was first observed in 1996 in cowpox virus infected LLC-PK1 pig kidney cells expressing cytokine response modifier A (CrmA), a viral caspase 1/8 inhibitor (<xref ref-type="bibr" rid="B45">45</xref>). In 1998, tumor necrosis factor-&#x3b1; (TNF&#x3b1;) was found to induce necroptosis of L-M cells (a mouse fibroblast cell line) in the presence of a caspase 8 inhibitor, suggesting that caspase 8 negatively regulates necroptosis (<xref ref-type="bibr" rid="B46">46</xref>). Today, it is well known that necroptosis can be triggered by TNF&#x3b1;, TNF-related apoptosis-inducing ligand (TRAIL), and Fas ligand, which activate the death receptor-mediated apoptosis pathway and lead to necroptosis when CASP8 activation is prevented by pharmacological caspase inhibitors (e.g., Z-VAD-FMK) or genetic depletion of fas-associated via death domain (FADD) (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Necroptosis is also triggered by the stimulation of pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) 3 and 4, DNA-dependent activator of interferon-regulatory factors (DAI), or cyclic GMP-AMP synthase (cGAS) (<xref ref-type="bibr" rid="B49">49</xref>&#x2013;<xref ref-type="bibr" rid="B51">51</xref>). Through signal transduction by PRRs, receptor-interacting protein kinase (RIPK) 1 is activated, RIPK3 is recruited, and a necrosome is formed (<xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>). RIPK1/RIPK3 further activates the mixed lineage kinase domain-like pseudokinase (MLKL) (<xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B55">55</xref>). MLKL translocates to the plasma and cytoplasmic membranes and promotes cell membrane rupture and cell death, with simultaneous spilling of intracellular content containing pro-inflammatory cytokines and DAMPs (<xref ref-type="bibr" rid="B56">56</xref>). The emission of intracellular contents from necroptotic cancer cells, together with the released cytokines and chemokines, renders necroptotic cells immunogenic and thus able to elicit tumor-specific CD8<sup>+</sup> T cell-mediated responses, resulting in potent anticancer responses (<xref ref-type="bibr" rid="B43">43</xref>).</p>
<p>Preventive immunization (gold standard vaccination assay) of mice with necroptotic cancer cells induced by ectopic RIPK3 expression can induce antitumor immunity. In a B16-OVA tumor model and even a RIPK3-deficient CT26 tumor model, MLKL mRNA treatment induced necroptotic cell death and subsequent antitumor immunity (<xref ref-type="bibr" rid="B57">57</xref>). Additionally, AAV-induced RIPK3 expression can promote necroptosis in the TME, enhance neoantigen presentation activity, and induce tumor-specific CD8<sup>+</sup> T-cell priming, resulting in secondary tumor control and improved therapeutic efficacy of immune checkpoint blockers in various tumor mouse models (<xref ref-type="bibr" rid="B58">58</xref>). Decreased RIPK3 expression has been reported in several types of cancer patients&#x2019; samples (<xref ref-type="bibr" rid="B59">59</xref>&#x2013;<xref ref-type="bibr" rid="B62">62</xref>). In head and neck squamous cell carcinoma (HNSCC) patients, the loss of RIPK1 and RIPK3 function caused by promoter hypermethylation is closely related with poor prognoses (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). In hepatocellular carcinoma (HCC) patients, increased RIPK1, RIPK3, and phosphorylated MLKL levels were positively correlated with increases in tumor-infiltrating CD3<sup>+</sup> and CD8<sup>+</sup> T-lymphocytes (<xref ref-type="bibr" rid="B65">65</xref>). Furthermore, it has been reported that a combination of radiotherapy, chemotherapy, and hyperthermia with Z-VAD-FMK, a necroptosis inducer/pan-caspase inhibitor, can increase macrophage activation, retard tumor growth, and induce immune cell infiltration into tumors through the release of DAMPs in B16 melanoma (<xref ref-type="bibr" rid="B66">66</xref>). These reports indicate that necroptosis by the activation of RIPK1/RIPK3/MLKL in the TME can induce APC maturation through the release of DAMPs and promote strong antitumor immunity by inducing tumor-specific CD8<sup>+</sup> T-cells.</p>
</sec>
<sec id="s3_2">
<title>Ferroptosis</title>
<p>Ferroptosis, initially identified in 2012 by Brent Stockwell&#x2019;s group, represents an iron-dependent form of non-apoptotic cell death that has recently been attributed with antitumor immune effects (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>). Ferroptosis is driven by excessive iron accumulation in the cell, leading to higher lipid reactive oxygen species (ROS) and unrestricted lipid peroxidation. This ultimately results in plasma membrane damage and rupture, leading to the emission of DAMPs. During ferroptosis, the oxidation of antigens and DAMPs, including HMGB1, can alter their antigenic features, thereby enhancing the immunogenicity of ferroptosis (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B69">69</xref>).</p>
<p>Glutathione (GSH) and GSH biosynthesis pathway proteins such as solute carrier family 7 member 11 (SLC7A11) and glutathione-glutathione peroxidase 4 (GPX4) can convert lipid peroxides to lipid alcohols, which suppress intracellular iron-induced lipid ROS (<xref ref-type="bibr" rid="B67">67</xref>). Therefore, conditions that inhibit glutathione biosynthesis or GPX4 can induce ferroptosis. Indeed, specific agents such as erastin (an SLC7A11 inhibitor) and RSL3 (a GPX4 inhibitor) can trigger ferroptosis, selectively eliminating cancer cells (<xref ref-type="bibr" rid="B70">70</xref>, <xref ref-type="bibr" rid="B71">71</xref>). Radiotherapy is known to induce ICD and recent evidence suggest that radiation may induce ferroptosis by increasing lipid ROS accumulation (<xref ref-type="bibr" rid="B72">72</xref>, <xref ref-type="bibr" rid="B73">73</xref>). Indeed, the depletion of ferroptosis-related gene reduces the efficacy of radiotherapy (<xref ref-type="bibr" rid="B72">72</xref>). Crucially, in preclinical models, a vaccination of ferroptotic cells protected against re-challenge with fibrosarcoma, providing critical evidence of ferroptosis as a form of ICD. A recent, important finding revealed a strong increase in lipid peroxidation in the early phase of ferroptosis, but not in the late phase. Early or late ferroptotic MCA205 cells were assessed using the &#x2018;gold standard vaccination assay&#x2019; in immunocompetent C57BL/6J mice. Interestingly, re-challenging &#x201c;vaccinated&#x201d; mice with live MCA205 cells revealed that only early ferroptotic cancer cells could induce a protective immune response against the fibrosarcoma (<xref ref-type="bibr" rid="B74">74</xref>). Moreover, it was demonstrated that extracellular HMGB1 and ATP were necessary for ICD caused by early ferroptotic cells (<xref ref-type="bibr" rid="B74">74</xref>). Specifically, pharmacological blockade of the ATP receptor (P2X7) using oxiATP reversed the tumor-protective effects of vaccination with early ferroptotic cancer cells. Finally, sorafenib, approved by the FDA in 2006 for late-stage renal cell carcinoma (RCC) management and in 2007 for advanced-stage hepatocellular carcinoma (HCC) therapy, is known to induce ferroptosis in multiple cancer cell lines (<xref ref-type="bibr" rid="B75">75</xref>, <xref ref-type="bibr" rid="B76">76</xref>). Sorafenib triggers ferroptosis through either mitochondrial iron accumulation or SLC7A11 inhibition (<xref ref-type="bibr" rid="B77">77</xref>). While some HCC patients benefit from sorafenib treatment, drug resistance typically develops. In recent years, researchers have been exploring new approaches to reverse sorafenib resistance in HCC by elucidating the mechanisms of resistance to sorafenib (<xref ref-type="bibr" rid="B78">78</xref>).</p>
</sec>
<sec id="s3_3">
<title>Disulfidptosis</title>
<p>It has recently been discovered that abnormal intracellular disulfide accumulation under glucose starvation conditions can induce a previously uncharacterized form of regulated cell death, referred to as &#x2018;disulfidptosis&#x2019; (<xref ref-type="bibr" rid="B79">79</xref>). Surprisingly, disulfidptosis requires glucose deprivation and high expression of SLC7A11, which has a negative role in ferroptosis induction, as above mentioned. This indicates that SLC7A11 plays an important role in either ferroptosis or disulfidptosis induction, depending on cellular conditions (<xref ref-type="bibr" rid="B80">80</xref>). Indeed, despite the well-established pro&#x2013;cell survival function of SLC7A11 in the context of ferroptosis induction, other studies have uncovered an unexpected role of SLC7A11 in promoting cell death under glucose deprivation conditions (<xref ref-type="bibr" rid="B79">79</xref>, <xref ref-type="bibr" rid="B81">81</xref>&#x2013;<xref ref-type="bibr" rid="B83">83</xref>). Several cancer cells rely on SLC7A11 to import cystine to maintain redox balance and cell survival. To regulate this balance, cells utilize the molecule nicotinamide adenine dinucleotide phosphate (NADPH) to rapidly convert toxic disulfides into non-toxic molecules. Under glucose-starvation conditions, NADPH was severely depleted in cells overexpressing SLC7A11, and disulfides such as cystine accumulated abnormally. The excessive accumulation of disulfide leads to the formation of abnormal disulfide bonds between actin backbone proteins, causing the disintegration of the cytoskeletal protein network and subsequent cell death (<xref ref-type="bibr" rid="B79">79</xref>). Thus, disulfidptosis represents a unique mode of cell death distinct from other metal-induced cell death forms, such as cuproptosis and ferroptosis.</p>
<p>As the study of disulfidptosis is in its infancy, we cannot conclusively state that disulfidptosis has ICD potential. However, gene expression analysis during disulfidptosis shows a correlation with the activation of gene sets for immune cell infiltration in the TME, which is one important result of ICD (<xref ref-type="bibr" rid="B84">84</xref>&#x2013;<xref ref-type="bibr" rid="B87">87</xref>). Furthermore, it has been recently reported that a GLUT1 inhibitor (known to induce disulfidoptosis) can induce ICD in HCC (<xref ref-type="bibr" rid="B88">88</xref>). Further studies are needed to investigate the role of disulfidptosis in cancer immunotherapy.</p>
</sec>
<sec id="s3_4">
<title>Cuproptosis</title>
<p>Copper (Cu) is an essential element in virtually all living organisms, and consequently, low levels of Cu in cells are harmful. Conversely, excessive intracellular copper accumulation also triggers cell death. Recently, a novel form of Copper (Cu)-dependent programmed cell death, termed &#x2018;cuproptosis,&#x2019; was reported by Tsvetkov et&#xa0;al. in 2022, suggesting a new strategy for cancer therapeutics (<xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B90">90</xref>). The main morphological features of cuproptosis include mitochondrial shrinkage, endoplasmic reticulum injury, and plasma membrane rupture, which is crucial for its ICD potential. The exact molecular mechanism underlying cuproptosis remains unclear, but recent studies have proposed some potential mechanisms (<xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B90">90</xref>). The mitochondrion is a major target of Cu-induced cell death. Intracellular Cu targets and binds to lipoylated components in the tricarboxylic acid (TCA) cycle, and aggregation of these Cu-bound lipoylated mitochondrial proteins, such as dihydrolipoamide S-acetyltransferase (DLAT), a subunit of the pyruvate dehydrogenase complex, and the subsequent reduction in iron-sulfur (Fe&#x2013;S) clusters, facilitates proteotoxic stress and induces cuproptosis. Cu ionophores, such as elesclomol, bind extracellular Cu and transport it to intracellular compartments, inducing cuproptosis. A genome-wide CRISPR screen identified mitochondrial ferredoxin 1 (FDX1) and lipoyl synthase (LIAS) as key regulators of cuproptosis, and genetic knockout of either FDX1 or LIAS attenuates Cu ionophore-induced cell death (<xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B91">91</xref>). FDX1 is known to contribute to both DLAT lipoylation and Fe-S cluster proteins degradation. Importantly, Cu chelators, such as tetrathiomolybdate (TTM), inhibit cuproptosis, whereas inhibitors of ferroptosis (Ferrostatin-1), necroptosis (Necrostatin-1), and oxidative stress (N-acetylcysteine; NAC) failed to suppress elesclomol-induced cuproptosis, suggesting that cuproptosis is mechanistically distinct from other forms of cell death (<xref ref-type="bibr" rid="B89">89</xref>, <xref ref-type="bibr" rid="B92">92</xref>, <xref ref-type="bibr" rid="B93">93</xref>). Copper complexes containing polypyridine ligands have been reported to enter the endoplasmic reticulum (ER) <italic>in situ</italic>, leading to increased ROS levels and ER-stress-induced ICD in breast cancer cells (<xref ref-type="bibr" rid="B94">94</xref>). Recent study has revealed that the combination of elesclomol and Cucl2 combination induces cuproptosis in non-small-cell lung cancer (NSCLC) cells and leads to the HMGB1 release (<xref ref-type="bibr" rid="B95">95</xref>). Interestingly, elesclomol selectively induces cuproptosis in melanoma and leukemic cells, suggesting its potential use in clinic&#xa0;(<xref ref-type="bibr" rid="B96">96</xref>). Furthermore, several anti-cancer effects have been evaluated using copper-based nanomaterials (<xref ref-type="bibr" rid="B97">97</xref>). The discovery of cuproptosis has prompted many researchers to explore its potential use in hepatocellular carcinoma therapy as hepatic cells are particularly rich in mitochondria compared to the other cell types, indicating a distinct vulnerability to cuproptosis in HCC (<xref ref-type="bibr" rid="B98">98</xref>). Conversely, several studies have found significantly upregulated Cu levels in hepatic tumor tissue and serum of HCC cancer patients, with elevated Cu levels in tumor cells contributing to immune escape by enhancing PD-L1 expression (<xref ref-type="bibr" rid="B99">99</xref>, <xref ref-type="bibr" rid="B100">100</xref>). In this context, several cuproptosis-related genes are currently under investigation to understand elesclomol resistance and provide insight into the potential use of cuproptosis induction for HCC therapy (<xref ref-type="bibr" rid="B101">101</xref>&#x2013;<xref ref-type="bibr" rid="B103">103</xref>).</p>
</sec>
<sec id="s3_5">
<title>Paraptosis</title>
<p>Paraptosis, first reported by Bredesen&#x2019;s group in 2000, is characterized by the extensive vacuolization of ER components and mitochondria swelling, while lacking apoptotic features. Paraptosis is a type of caspase-independent programmed cell death (<xref ref-type="bibr" rid="B104">104</xref>). In most cases, paraptosis is mediated by human insulin-like growth factor I receptor (IGFIR) and induced by the downstream MAPK/ERK and JNK/SAPK pathways following ER stress pathway activation. Therefore, paraptosis can be rescued by specific inhibition of these kinases. Indeed, the MAPK activator elaiophylin induces paraptosis in ovarian cancer cells, and gene expression analysis showed that elaiophylin activates the ER-stress pathway, suggesting that ER-stress pathway activation is crucial for the execution of paraptosis (<xref ref-type="bibr" rid="B105">105</xref>). A member of TNF receptor superfamily, TNFRSF19, promotes ER-stress via MAPK pathway activation and induces paraptosis in triple negative breast cancer cells (<xref ref-type="bibr" rid="B106">106</xref>). A recent study demonstrated that the deletion of the pancreatic ER kinase (PKR)-like ER kinase (PERK) in cancer cells induces paraptosis (<xref ref-type="bibr" rid="B107">107</xref>). During ER stress, autophosphorylated PERK dissociates from its negative regulator and phosphorylates several targets, including the eukaryotic translation initiation factor 2&#x3b1; (eIF2&#x3b1;), which triggers the expression of the activating transcription factor 4 (ATF4) that transiently contributes to cancer cell survival. Paraptosis is triggered by proteostasis alterations, a process heavily dependent on the SEC61 translocon complex. Dysregulation of the SEC61 complex by the regulatory subunit SEC61&#x3b2; drives paraptosis by altering the trafficking of proteins through the ER. PERK and ATF4 serve as upstream negative regulators of SEC61&#x3b2;-mediated paraptosis. However, the mechanistic insights of the PERK, ATF4, and SEC61&#x3b2; crosstalk in the regulation of anti-tumor immunity are yet to be elucidated. Most importantly, PERK inhibition in ER-stressed malignant cells triggers DAMPs release and activates anti-tumor T cell immune responses, suggesting that paraptosis is ICD in cancer cells (<xref ref-type="bibr" rid="B107">107</xref>). Interestingly, it has also been reported that paraptosis is triggered by natural products, showing the ICD potential of paraptosis. Morusin, a prenylated flavonoid isolated from the root bark of the Morus mulberry plant, could effectively induce paraptosis-like epithelial ovarian cancer cell death by amplifying the oxidative stress of the ER and mitochondria (<xref ref-type="bibr" rid="B108">108</xref>). Another study has found that the natural anthraquinone compound, novel rhein derivative 4a, induces paraptosis-like cell death in ovarian cancer cells (<xref ref-type="bibr" rid="B109">109</xref>). Indoleamine 2,3-dioxygenase (IDO), which is upregulated in tumor cells, can reprogram tryptophan/kynurenine metabolism to facilitate immune escape. IDO inhibitor can reverse the tumor microenvironment and elicit the host immune system (<xref ref-type="bibr" rid="B110">110</xref>). Therefore, a therapeutic strategy synergizing paraptosis induction and IDO inhibition may be greatly advantageous in activating systemic immunity. Indeed, a paraptosis inducer prepared by the assembly of copper ions (Cu2+), morusin, and IDO inhibitor (NLG919) through noncovalent interactions could induce cancer cell paraptosis through mitochondrial and ER vacuolation. This contributes to releasing large amounts of DAMPs to recruit DCs for activating antitumor immunity in a 4T-1 breast cancer mouse model (<xref ref-type="bibr" rid="B111">111</xref>).</p>
</sec>
<sec id="s3_6">
<title>Parthanatos</title>
<p>Parthanatos is a form of RCD characterized by necrotic-like morphology. Poly (ADP-ribose) polymerase-1 (PARP-1), a nuclear protein that plays a crucial role in DNA repair, genomic stability, and transcription is the key molecule in the parthanatos mechanism (<xref ref-type="bibr" rid="B112">112</xref>, <xref ref-type="bibr" rid="B113">113</xref>). Activation of PARP-1 by parthanatos induces the release of immunogenic alarmins, primarily of HMGB1. Parthanatos is triggered by the hyperactivation of PARP-1 in response to extremely high and prolonged alkylating DNA damage induced by ROS or alkylating agents, resulting in the depletion of cellular energy, the mitochondrial release of apoptosis-inducing factor (AIF), and the production of excess poly (ADP-ribose) (PAR) polymers, followed by large-scale DNA fragmentation (<xref ref-type="bibr" rid="B114">114</xref>). In 2016, macrophage migration inhibitory factor (MIF) nuclease was identified as a crucial factor in the induction of parthanatos by forming a MIF/AIF complex (<xref ref-type="bibr" rid="B115">115</xref>). Several anti-cancer drugs efficaciously induce parthanatos-dependent cancer cell death in several types of cancers (<xref ref-type="bibr" rid="B116">116</xref>&#x2013;<xref ref-type="bibr" rid="B118">118</xref>). Oxaliplatin, considered an ICD inducer chemotherapeutic agent, has been found to induce parthanatos in oral squamous cell carcinoma (OSCC) cells <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B119">119</xref>). Cytarabine/AraC is known to induce apoptosis in several types of acute myeloid leukemia (AML) cell lines. However, a recent study has revealed that AraC also induces parthanatos in OCI-AML3 cells, suggesting that cell type or AraC sensitivity may alter the consequences of AraC treatment (<xref ref-type="bibr" rid="B120">120</xref>).</p>
<p>A recent study shows that mixed lineage kinase domain-like pseudokinase (MLKL) deficiency in hepatocellular carcinoma cells restricts ER Mg2+ release and mitochondrial Mg2+ uptake, leading to ER dysfunction, mitochondrial oxidative stress, and, ultimately, metabolic-stress-induced parthanatos (<xref ref-type="bibr" rid="B121">121</xref>). Therefore, MLKL deficiency in HCC cells suppresses orthotopic tumor growth, activates the anti-tumor immune response, and enhances the therapeutic effect of immune checkpoint blockade in syngeneic HCC tumor mouse models. The use of a PARP-1 inhibitor to block parthanatos could then restore tumor growth and immune evasion in MLKL-knockout HCC tumors. Since MLKL is a critical executioner of necroptosis, this report elucidates a new role for MLKL in negatively regulating parthanatos in HCC.</p>
</sec>
<sec id="s3_7">
<title>Alkaliptosis</title>
<p>Alkaliptosis, a pH-dependent regulated cell death process triggered by the small molecular compound JTC801, has recently been identified as a novel approach for malignant tumor treatment, particularly in pancreatic cancer through the screening of new anti-cancer drugs (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B123">123</xref>). Indeed, <italic>in vivo</italic> experiments in mice showed that JTC801 selectively targets pancreatic ductal adenocarcinoma (PDAC) cells without harming normal cells. Two major signaling pathways, the ATPase H+ transporting V0 subunit D1 (ATP6V0D1)-signal transducer and activator of transcription 3 (STAT3) pathway and the NF-&#x3ba;B pathway, are reported to contribute to the induction of alkaliptosis (<xref ref-type="bibr" rid="B122">122</xref>, <xref ref-type="bibr" rid="B124">124</xref>, <xref ref-type="bibr" rid="B125">125</xref>). Blocking other cell death modes such as apoptosis, necroptosis, and ferroptosis did not prevent JTC801-induced cell death. Mass spectrometry identified ATP6V0D1 as a JTC801 target (<xref ref-type="bibr" rid="B125">125</xref>). ATP6V0D1, a member of the vacuolar ATPase (V-ATPase) family, regulates the acidification of intracellular organelles. It forms a complex with STAT3 in lysosomes, leading to lysosomal acidification and cytosolic alkalinization, thus inducing alkaliptosis. However, inhibiting ATP6V0D1 fails to prevent JTC801-induced lysosomal acidification, indicating the potential involvement of a compensatory mechanism (<xref ref-type="bibr" rid="B126">126</xref>). Therefore, the precise mechanism remains unclear. JTC801 activates NF-&#x3ba;B-dependent carbonic anhydrase 9 (CA9) downregulation (<xref ref-type="bibr" rid="B127">127</xref>). CA9 regulates pH by catalyzing the reversible hydration of carbon dioxide to carbonic acid and is overexpressed in many types of solid cancers, including PDAC, where it promotes tumor growth by inhibiting intracellular alkalinization. JTC801-induced alkaliptosis is capable of activating NF-kb making it another potential means of inducing ICD. Most importantly, JTC801-induced alkaliptosis of cancer cells can lead to the release of HMGB1 into the cell culture supernatants. This release of HMGB1 from the nucleus involves nuclear DNA damage signaling and can be inhibited by the FA complementation group D2 (FANCD2)-dependent DNA repair pathways (<xref ref-type="bibr" rid="B128">128</xref>). It has been reported that extracellular HMGB1 binds to its receptor, advanced glycosylation end-product-specific receptor (AGER, also known as RAGE), in macrophages and activates the cGAS-STING pathway-mediated immunity (<xref ref-type="bibr" rid="B128">128</xref>). Another recent report revealed that acyl-CoA synthetase short-chain family member 2 (ACSS2), responsible for producing acetyl-CoA and leading to NF-&#x3ba;B acetylation, subsequently activates the NF-&#x3ba;B pathway and CA9 downregulation, promoting alkaliptosis in PDAC cells (<xref ref-type="bibr" rid="B129">129</xref>). Thus, alkaliptosis is potentially ICD-like, but it is not well-characterized thus far as a cancer immunotherapy and needs to be further examined in the future.</p>
</sec>
<sec id="s3_8">
<title>Autophagy and autosis</title>
<p>Autophagy, a well-known programmed cell death mode, plays a paradoxical role in the anti-tumor response. Autophagy is a self-degradative type of cell death accompanied by large-scale autophagic vacuolization of the cytoplasm, resulting in a vacuolated appearance in response to stressors, such as nutrient deprivation (<xref ref-type="bibr" rid="B130">130</xref>). Autophagy also serves as an advanced system for the elimination of DAMPs and PAMPs, contributing to the maintenance of immune homeostasis (<xref ref-type="bibr" rid="B131">131</xref>&#x2013;<xref ref-type="bibr" rid="B134">134</xref>). In this role, autophagy basically suppresses inflammatory cytokine production and inflammasome activation, reducing ICD-mediated immune activation. Autophagy also aids tumor cells in evading immune surveillance by inhibiting antitumor immune responses. For example, autophagy degrades the MHC-I complex, thereby preventing immune cell recognition in a pancreatic cancer mouse model (<xref ref-type="bibr" rid="B135">135</xref>, <xref ref-type="bibr" rid="B136">136</xref>). In contrast, the autophagy inhibitor chloroquine (CQ) increases MHC-I complexes and results in enhanced antitumor immune responses (<xref ref-type="bibr" rid="B135">135</xref>). Overall, evidence suggests that autophagy is immunosuppressive and linked to cancer survival and proliferation. However, several studies have also revealed that autophagy also contributes to antitumor functions depending on its level of activation or strength (<xref ref-type="bibr" rid="B137">137</xref>, <xref ref-type="bibr" rid="B138">138</xref>). High-level autophagy and not mild autophagy, is able to promote ICD in tumor cells by releasing DAMPs from dead cells, which can inflame the TME and activate anti-tumor immunity. During ICD, autophagosomes including tumor antigens and DAMPs are released into extracellular space and taken up by APCs (<xref ref-type="bibr" rid="B139">139</xref>). Mechanistically, during autophagy in response to ICD induction, it has been reported that ATP is secreted from the plasma membrane through lysosomes and autolysosomes (<xref ref-type="bibr" rid="B17">17</xref>). Most importantly, suppression of autophagy results in diminished release of ATP and DAMPs from dying tumor cells treated with anthracycline chemotherapeutic agents, indicating an essential role of autophagy in ICD (<xref ref-type="bibr" rid="B140">140</xref>, <xref ref-type="bibr" rid="B141">141</xref>). Autophagy has also recently been demonstrated to have a role in necroptosis. Autophagy induction by obatoclax results in FADD/RIPK1/RIPK3 recruitment to the autophagosomal membranes by interaction with Atg5, suggesting that autophagy may promote necroptosis via the assembly of the necrosome on autophagosomes (<xref ref-type="bibr" rid="B142">142</xref>). Thus, high-level autophagy is capable of promoting cancer cell death and releasing DAMPs from deceased cells. This process can remodel the TME and activate anti-tumor immunity (<xref ref-type="bibr" rid="B138">138</xref>).</p>
<p>Recently, a novel form of autophagy gene-dependent, Na<sup>+</sup>,K<sup>+</sup>-ATPase-regulated, non-apoptotic cell death, termed &#x2018;autosis&#x2019;, which is induced by excessive autophagy, prolonged autophagy-inducing peptides (HIV1-Tat fused Beclin 1, Tat-BECN1) treatment, starvation, and hypoxia-ischemia, and characterized by the disappearance of the endoplasmic reticulum and focal swelling of the perinuclear space has been identified (<xref ref-type="bibr" rid="B143">143</xref>, <xref ref-type="bibr" rid="B144">144</xref>). Autosis is associated with plasma membrane rupture, suggesting the release of intracellular components that can increase immunogenicity. Indeed, it has been reported that Tat-BECN1 treatment triggered autosis enhances immunogenicity <italic>in vivo</italic> (<xref ref-type="bibr" rid="B145">145</xref>).</p>
<p>It has also been recently reported that myxoma virus (MYXV)-infected tumor-specific T (T<sup>MYXV</sup>) cells expressing a chimeric antigen receptor (CAR), &#x2018;CAR-T<sup>MXYV</sup>&#x2019;, eradicate antigen-loss tumors by inducing tumor autosis (<xref ref-type="bibr" rid="B146">146</xref>). Mechanistically, cytotoxic T cell-derived IFN&#x3b3; synergistically activates CAR-T<sup>MXYV</sup> mediated autophagosome formation and executes cancer cell autosis. This method can induce both cytotoxicity and tumor antigen MYXV to antigen-deficient (cold) tumor bed in a B16 melanoma mouse model, resulting in a boost to adaptive immunity similar to ICD induction.</p>
<p>Depending on the cancer cell types and circumstances in the TME, autophagy can be both anti-cancer and pro-cancer, which should raise concerns when choosing autophagy modulators for clinical studies and use (<xref ref-type="bibr" rid="B147">147</xref>, <xref ref-type="bibr" rid="B148">148</xref>). Therefore, autosis induction, instead of autophagy inhibition or induction, may be a more reasonable target for consideration as an anti-cancer treatment.</p>
</sec>
<sec id="s3_9">
<title>Pyroptosis</title>
<p>The term &#x201c;pyroptosis&#x201d; was originally coined to indicate proinflammatory (from the Greek &#x201c;pyro&#x201d; referring to fire) programmed cell death (&#x201c;ptosis&#x201d;) during bacterial infection in macrophages. Now, it is known that pyroptosis also occurs in cancer cells and induces anti-tumor immunity (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B149">149</xref>, <xref ref-type="bibr" rid="B150">150</xref>). Pyroptosis is a programmed necrotic cell death mediated by pore-forming gasdermin (GSDM) proteins (<xref ref-type="bibr" rid="B151">151</xref>). Morphological characteristics of pyroptosis include cytoplasmic swelling, DNA fragmentation, and pore formation, resulting in the emission of intracellular contents and proinflammatory cytokines (e.g., IL-1&#x3b2;, IL-18, IL-33, and HMGB1). Pyroptosis is executed by inflammasome-dependent or -independent mechanisms (<xref ref-type="bibr" rid="B152">152</xref>). Inflammasomes, multi-protein oligomers, are divided into NOD-like receptors (NLRs) (e.g., NLRP1, NLRP3, and NLRC4, with NLRP3 being the most-studied inflammasome) and non-NLRs (e.g., AIM2; AIM2 is activated by cytosolic bacterial, viral, and host dsDNA) (<xref ref-type="bibr" rid="B153">153</xref>&#x2013;<xref ref-type="bibr" rid="B156">156</xref>). The inflammasome is activated by PAMPs and DAMPs and triggers the activation of caspase-1, known as canonical inflammasome activation. Active caspase-1 cleaves gasdermin D (GSDMD) and further matures IL-1&#x3b2; and IL-18, leading to pyroptosis (<xref ref-type="bibr" rid="B157">157</xref>&#x2013;<xref ref-type="bibr" rid="B159">159</xref>). LPS also activates the non-canonical inflammasome, targeting caspase-4/5/11 (human caspase-4/5 and mouse caspase-11), followed by cleavage of GSDMD (<xref ref-type="bibr" rid="B160">160</xref>&#x2013;<xref ref-type="bibr" rid="B165">165</xref>). The cleaved N-terminal GSDMD acts as the &#x201c;executioner&#x201d;, forming pores in the cell membrane (<xref ref-type="bibr" rid="B166">166</xref>, <xref ref-type="bibr" rid="B167">167</xref>). Gasdermin E (GSDME, also called DFNA5) was recently identified as another pyroptotic &#x201c;executioner&#x201d; and suppresses tumor growth by activating anti-tumor immunity (<xref ref-type="bibr" rid="B168">168</xref>). During chemotherapy, in GSDME expressing cells, GSDME can be cleaved and activated by caspase-3, converting cells from apoptotic to secondary necrotic/pyroptotic (<xref ref-type="bibr" rid="B169">169</xref>, <xref ref-type="bibr" rid="B170">170</xref>). In the TME of GSDME expressing tumors (breast, colorectal and melanoma), the function and number of DCs, cytotoxic lymphocytes and NK cells are increased (<xref ref-type="bibr" rid="B168">168</xref>). Another study demonstrates that the combination of a BRAF inhibitor and MEK inhibitor activates caspase-3 GSDME-mediated pyroptosis in melanoma, leading to increased immune response and tumor suppression in melanoma-bearing mice (<xref ref-type="bibr" rid="B171">171</xref>). It has also been reported that the cyclin-dependent kinase (CDK) -1, -2 and -9 inhibitor, Dinaciclib, induces ICD and has confirmed anti-tumor effects in syngeneic MC38, CT26 colon and MB49 bladder cancer mouse models (<xref ref-type="bibr" rid="B172">172</xref>). Dinaciclib-mediated ICD has been further evaluated as a GSDME-mediated pyroptosis in several triple negative breast cancer cell lines and a 4T1 breast cancer mouse model (<xref ref-type="bibr" rid="B173">173</xref>). Notably, GSDME is silenced in multiple tumors through GSDME DNA methylation, and therefore, methyltransferase inhibitors (e.g., decitabine) can increase GSDME expression and inhibit tumor growth (<xref ref-type="bibr" rid="B174">174</xref>, <xref ref-type="bibr" rid="B175">175</xref>). Indeed, decreased GSDME expression in oral squamous cell carcinoma (OSCC) is associated with poor prognosis (<xref ref-type="bibr" rid="B176">176</xref>).Thus, this evidence suggests that GSDME mediated pyroptosis plays an essential role in tumor suppression. In addition to GSDMD- or GSDME-mediated pyroptosis, other GSDM-mediated pyroptosis pathways have been reported. For example, granzymes (Gzms) secreted from CTL or NK cells can induce pyroptosis. GzmA cleaves GSDMB and triggers pyroptosis (<xref ref-type="bibr" rid="B177">177</xref>). GzmB cleaves both Caspase-3 and GSDME, amplifying GzmB-mediated pyroptosis (<xref ref-type="bibr" rid="B168">168</xref>, <xref ref-type="bibr" rid="B178">178</xref>, <xref ref-type="bibr" rid="B179">179</xref>). Since cancer pyroptosis results in immune cell activation and these activated cells secrete granzymes in the TME, induction of cancer pyroptosis may be one of the reasonable cancer immunotherapeutic strategies. Whether there are any other additional mechanisms of cancer pyroptosis will require further investigation.</p>
</sec>
<sec id="s3_10">
<title>Atypical ISGs induced pyroptosis</title>
<p>In most instances, type I IFNs are crucial for subsequent immune response activation but are not mandatory for the induction of ICD itself. Notably, the release of type I IFNs serves as a biomarker for the completion of ICD (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>) (<xref ref-type="bibr" rid="B37">37</xref>). However, recent evidence highlights that, beyond type I IFN production, the response of tumor cells to type I IFNs represents an essential pathway for eliciting effective antitumor responses following ICD induction. For instance, the induction of ICD by anthracycline-based chemotherapies and radiotherapy relies heavily on their capacity to activate IFN-dependent gene expression programs within tumor cells, thereby facilitating the generation of robust antitumor immune responses (<xref ref-type="bibr" rid="B180">180</xref>, <xref ref-type="bibr" rid="B181">181</xref>). Regarding whether modulating the IFN response promotes ICD, it was recently shown that the IFN inducible Z-form nucleic acid binding protein 1 (ZBP1) can trigger ICD in <italic>Ripk1</italic>-/- cells (<xref ref-type="bibr" rid="B182">182</xref>). However, ZBP1 induction by IFN alone appears insufficient to induce ICD, implying the involvement of other unidentified factors. Moreover, although cGAS-STING or retinoic acid inducible gene I (RIG-I) pathway activation can induce ICD, the precise mechanisms beyond type I IFN production remain unclear (<xref ref-type="bibr" rid="B183">183</xref>). While numerous studies underscore the significance of the type I IFN response in ICD induction and its intrinsic ability to enhance antitumor immunity, the extent to which modulating or enhancing IFN responses directly promotes ICD remains insufficiently characterized. Consequently, it is hypothesized that genetic factors regulate IFN-mediated ICD, and targeting these factors may hold therapeutic promise, particularly considering the elevated levels of interferon production in the tumor microenvironment.</p>
<p>The production and signaling of type I IFNs are tightly regulated (<xref ref-type="bibr" rid="B184">184</xref>). Our recent discovery reveals that the depletion of ubiquitin-specific protease 18 (USP18), a major negative regulator of IFN signaling, selectively induces cancer cell ICD, specifically pyroptosis (<xref ref-type="bibr" rid="B185">185</xref>, <xref ref-type="bibr" rid="B186">186</xref>). We identified that nuclear USP18 diminishes binding of IFN regulated transcription factors to their corresponding DNA motifs in cooperation with NF-&#x3ba;B. Consequently, the suppression of USP18 not only enhances the expression of canonical IFN-stimulated genes (ISGs) but also activates a set of atypical ISGs and NF-&#x3ba;B target genes that induce cancer pyroptosis. Importantly, partial loss of <italic>Usp18</italic> in mice does not disrupt normal hematopoiesis, and mice and humans heterozygous for Usp18 are healthy and normal (<xref ref-type="bibr" rid="B186">186</xref>&#x2013;<xref ref-type="bibr" rid="B188">188</xref>). Our recent study further demonstrates that USP18 depletion in the myeloid lineage exerts an anti-cancer effect by reprogramming M2 macrophages to M1 macrophages in the tumor microenvironment (<xref ref-type="bibr" rid="B189">189</xref>). These findings suggest a promising therapeutic opportunity for targeting USP18 in clinical applications.</p>
<p>Additionally, we observed a clear translocation of HMGB1 from the nucleus to the cytoplasm in <italic>Usp18</italic>
<sup>+/-</sup> and <italic>Usp18</italic>
<sup>-/-</sup> MC38 colon tumors, representing an ICD associated event in solid tumors. Significantly, higher infiltration of CD8<sup>+</sup> T cells was noted in these tumors, suggesting that the depletion of <italic>Usp18</italic> in solid tumors can induce ICD and enhance the immune response. We also observed higher numbers of CD8<sup>+</sup> T and activated CD8<sup>+</sup> T cells in host splenocytes of recipients of <italic>Usp18</italic>
<sup>+/&#x394;</sup> AML cells (<xref ref-type="bibr" rid="B186">186</xref>). Finally, a significant reduction in tumor development was observed in the group of mice vaccinated with IFN-treated <italic>Usp18</italic>
<sup>+/-</sup> cells, as assessed by the gold standard vaccination assay in B16F10 and MC38 tumor mouse models. Importantly, this vaccine effect is attributed to the enhancement of tumor-infiltrating activated CD8<sup>+</sup> T cells, a crucial component for the ICD-induced vaccine response. Thus, ICD induced by targeting <italic>Usp18</italic> occurs in certain solid cancers (<xref ref-type="bibr" rid="B186">186</xref>).</p>
<p>Among the atypical ISGs in IFN treated <italic>USP18</italic> depleted cancer cells, we identified PLK2 as one mediator of the observed ICD (<xref ref-type="bibr" rid="B186">186</xref>). Enhanced levels of <italic>PLK2</italic> correlated with high levels of caspase-3 and GSDME cleavage, a hallmark of pyroptosis, in IFN treated <italic>USP18<sup>-/-</sup>
</italic> cancer cells. Importantly, we demonstrated that the ectopic expression of PLK2, independent of its kinase activity, in several types of cancer cells promoted the caspase-3 processing, GSDME cleavage, DAMPs release, and cell death, albeit without IL-1&#x3b2; secretion. Since the NLRP3 inflammasome can be formed and activated by DAMPs, PLK2-induced DAMP release could also be crucial for GSDMD pathway activation in the USP18-depleted tumor environment <italic>in vivo</italic>. Notably, the suppression of PLK2 kinase activity enhances the protein level of PLK2. Consequently, both a USP18 inhibitor and a PLK2 kinase inhibitor can induce cancer pyroptosis and hold significant potential as cancer therapeutic agents (<xref ref-type="bibr" rid="B186">186</xref>).</p>
</sec>
<sec id="s3_11">
<title>Lysosomal cell death</title>
<p>Lysosomal cell death (LCD), is a form of RCD mediated by lysosomal damage triggered lysosomal membrane permeabilization (LMP). Christian de Duve first identified LCD in 1983, and the term &#x201c;lysosomal cell death&#x201d; was later coined in 2000 (<xref ref-type="bibr" rid="B190">190</xref>, <xref ref-type="bibr" rid="B191">191</xref>). Lysosomal damage can be triggered by various agents such as chloroquine, lipid metabolites, ROS, and certain anti-cancer drugs (e.g., sorafenib). Growing evidence suggests that mild lysosomal damage results in cell apoptosis, while extensive damage can induce ICD. This highlights LCD as a rational target for promising cancer immunotherapy.</p>
<p>During LMP, the release of cathepsins and ROS plays a crucial role in ICD. For example, cathepsin D mediated necroptosis, cathepsin B- or G- mediated pyroptosis and ROS-mediated ferroptosis have been reported (<xref ref-type="bibr" rid="B192">192</xref>&#x2013;<xref ref-type="bibr" rid="B197">197</xref>). A recent study demonstrated that the lysosomal inhibitor DC661 induces lysosomal lipid peroxidation followed by LMP and ICD, involving necroptosis, ferroptosis, and pyroptosis (<xref ref-type="bibr" rid="B198">198</xref>). Interestingly, these forms of cell death cannot be rescued by either ICD inhibitors or cathepsin inhibitors but can be reversed by the antioxidant N-acetylcysteine (NAC), highlighting the uniqueness of DC661-induced specific LCD. Importantly, mice vaccinated with DC661-treated cells exhibited secondary tumor rejection, a critical indication that DC661-mediated tumor cell death is immunogenic in nature.</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Altogether, these findings suggest that appropriate induction of ICD can lead to successful control of multiple neoplasms through (immuno)therapy. ICD has garnered significant attention in cancer research, as it possesses the capability to enhance the body&#x2019;s immune response to recognize and eliminate cancer cells.</p>
<p>In this review, we provide a summary of both previous and recent studies related to cancer ICD. Notably, numerous novel cell death modalities have been discovered within the last 20 years, cultivating a deeper understanding of which cell death modes exhibit ICD-like characteristics (e.g., paraptosis is now recognized as ICD). Moreover, our study revealed that hyper type I IFN response-mediated atypical ISGs selectively induce cancer ICD. It is increasingly evident that a single cell death mode can transition to different types of cell death, including ICD, under specific conditions. These immunostimulatory properties of ICD render ICD-inducing agents attractive candidates for cancer immune-monotherapy, with initial results from <italic>in vitro</italic> experiments and preclinical models suggesting a promising, viable path forward. However, numerous unknown factors still impede progress in ICD-mediated cancer immunotherapy, particularly concerning the development of reagents for tumor-specific ICD induction in clinical settings, strategies for reliably inducing ICD across different cancer types without inducing toxicity and resistance, and understanding the mechanisms by which various ICD modes enable protective anti-tumor immunity.</p>
<p>Currently, only a limited number of cytotoxic agents and methodologies (e.g., anthracyclines, oxaliplatin, radiation therapy, oncolytic viruses) have demonstrated the ability to induce ICD, with approved clinical use restricted to certain cancer types due to the genetic diversity, tissue origin, and local microenvironment of the tumor (<xref ref-type="bibr" rid="B35">35</xref>). Therefore, researchers are also actively exploring novel, clinically viable combinatorial strategies to enhance therapeutic potential by combining ICD with other approved regimens, including ICB (<xref ref-type="bibr" rid="B172">172</xref>, <xref ref-type="bibr" rid="B199">199</xref>). Indeed, several combinations of ICD inducers are currently being investigated in clinical trials for specific types of cancer (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B200">200</xref>, <xref ref-type="bibr" rid="B201">201</xref>). Moreover, recent studies reveal that certain compounds/agents (or their combinations) have ICD-inducing abilities with different cell death modalities (<xref ref-type="bibr" rid="B202">202</xref>, <xref ref-type="bibr" rid="B203">203</xref>). It is also noteworthy that strategies for drug delivery, including nanoparticles-mediated ICD induction, are under development (<xref ref-type="bibr" rid="B97">97</xref>, <xref ref-type="bibr" rid="B204">204</xref>&#x2013;<xref ref-type="bibr" rid="B206">206</xref>). However, the majority of agents/methodologies for ICD induction have only been tested through <italic>in vitro</italic> experiments and preclinical animal models. Further investigations, including clinical studies involving newly identified agents/methodologies with a focus on ICD, will provide more valuable evidence for the treatment of cancer. We anticipate that the evolution of ICD induction from current and future studies will increasingly take center stage in modern cancer control.</p>
</sec>
<sec id="s5" sec-type="author-contributions">
<title>Author contributions</title>
<p>K-iA: Conceptualization, Writing &#x2013; original draft. SM: Writing &#x2013; review &amp; editing. ML: Writing &#x2013; review &amp; editing. D-EZ: Funding acquisition, Supervision, Writing &#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s6" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. These studies were supported by NIH R01 CA232147 and R01 CA177305 to D-EZ.</p>
</sec>
<sec id="s7" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s8" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname> <given-names>P</given-names>
</name>
<name>
<surname>Allison</surname> <given-names>JP</given-names>
</name>
</person-group>. <article-title>The future of immune checkpoint therapy</article-title>. <source>Science</source>. (<year>2015</year>) <volume>348</volume>:<fpage>56</fpage>&#x2013;<lpage>61</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aaa8172</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiravand</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Khodadadi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kashani</surname> <given-names>SMA</given-names>
</name>
<name>
<surname>Hosseini-Fard</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Hosseini</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sadeghirad</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Immune checkpoint inhibitors in cancer therapy</article-title>. <source>Curr Oncol</source>. (<year>2022</year>) <volume>29</volume>:<page-range>3044&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/curroncol29050247</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Havel</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Chowell</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>TA</given-names>
</name>
</person-group>. <article-title>The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy</article-title>. <source>Nat Rev Cancer</source>. (<year>2019</year>) <volume>19</volume>:<page-range>133&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41568-019-0116-x</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waldman</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Fritz</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Lenardo</surname> <given-names>MJ</given-names>
</name>
</person-group>. <article-title>A guide to cancer immunotherapy: from T cell basic science to clinical practice</article-title>. <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>20</volume>:<page-range>651&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ansell</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Lesokhin</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Borrello</surname> <given-names>I</given-names>
</name>
<name>
<surname>Halwani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Scott</surname> <given-names>EC</given-names>
</name>
<name>
<surname>Gutierrez</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>PD-1 blockade with nivolumab in relapsed or refractory Hodgkin&#x2019;s lymphoma</article-title>. <source>N Engl J Med</source>. (<year>2015</year>) <volume>372</volume>:<page-range>311&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1411087</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garon</surname> <given-names>EB</given-names>
</name>
<name>
<surname>Rizvi</surname> <given-names>NA</given-names>
</name>
<name>
<surname>Hui</surname> <given-names>R</given-names>
</name>
<name>
<surname>Leighl</surname> <given-names>N</given-names>
</name>
<name>
<surname>Balmanoukian</surname> <given-names>AS</given-names>
</name>
<name>
<surname>Eder</surname> <given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>Pembrolizumab for the treatment of non-small-cell lung cancer</article-title>. <source>N Engl J Med</source>. (<year>2015</year>) <volume>372</volume>:<page-range>2018&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1501824</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paucek</surname> <given-names>RD</given-names>
</name>
<name>
<surname>Baltimore</surname> <given-names>D</given-names>
</name>
<name>
<surname>Li</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>The cellular immunotherapy revolution: arming the immune system for precision therapy</article-title>. <source>Trends Immunol</source>. (<year>2019</year>) <volume>40</volume>:<fpage>292</fpage>&#x2013;<lpage>309</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2019.02.002</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Chung</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunogenic cell death in cancer immunotherapy</article-title>. <source>BMB Rep</source>. (<year>2023</year>) <volume>56</volume>:<page-range>275&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5483/BMBRep.2023-0024</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palanivelu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>LT</given-names>
</name>
</person-group>. <article-title>Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1038226</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1038226</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Buque</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Immunogenic cell death in cancer and infectious disease</article-title>. <source>Nat Rev Immunol</source>. (<year>2017</year>) <volume>17</volume>:<fpage>97</fpage>&#x2013;<lpage>111</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri.2016.107</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bruni</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Approaches to treat immune hot, altered and cold tumours with combination immunotherapies</article-title>. <source>Nat Rev Drug Discovery</source>. (<year>2019</year>) <volume>18</volume>:<fpage>197</fpage>&#x2013;<lpage>218</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41573-018-0007-y</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Humeau</surname> <given-names>J</given-names>
</name>
<name>
<surname>Buque</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors</article-title>. <source>Nat Rev Clin Oncol</source>. (<year>2020</year>) <volume>17</volume>:<page-range>725&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41571-020-0413-z</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Senovilla</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vitale</surname> <given-names>I</given-names>
</name>
<name>
<surname>Vacchelli</surname> <given-names>E</given-names>
</name>
<name>
<surname>Adjemian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Agostinis</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Consensus guidelines for the detection of immunogenic cell death</article-title>. <source>Oncoimmunology</source>. (<year>2014</year>) <volume>3</volume>:<fpage>e955691</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4161/21624011.2014.955691</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Immunogenic cell death in cancer therapy</article-title>. <source>Annu Rev Immunol</source>. (<year>2013</year>) <volume>31</volume>:<fpage>51</fpage>&#x2013;<lpage>72</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-100008</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Casares</surname> <given-names>N</given-names>
</name>
<name>
<surname>Pequignot</surname> <given-names>MO</given-names>
</name>
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ghiringhelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Roux</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chaput</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death</article-title>. <source>J Exp Med</source>. (<year>2005</year>) <volume>202</volume>:<page-range>1691&#x2013;701</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20050915</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Panaretakis</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Apetoh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ghiringhelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular characteristics of immunogenic cancer cell death</article-title>. <source>Cell Death Differ</source>. (<year>2008</year>) <volume>15</volume>:<fpage>3</fpage>&#x2013;<lpage>12</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/sj.cdd.4402269</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins</surname> <given-names>I</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Michaud</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sukkurwala</surname> <given-names>AQ</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular mechanisms of ATP secretion during immunogenic cell death</article-title>. <source>Cell Death Differ</source>. (<year>2014</year>) <volume>21</volume>:<fpage>79</fpage>&#x2013;<lpage>91</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cdd.2013.75</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fucikova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Kasikova</surname> <given-names>L</given-names>
</name>
<name>
<surname>Petroni</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yamazaki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Detection of immunogenic cell death and its relevance for cancer therapy</article-title>. <source>Cell Death Dis</source>. (<year>2020</year>) <volume>11</volume>:<fpage>1013</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-020-03221-2</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obeid</surname> <given-names>M</given-names>
</name>
<name>
<surname>Panaretakis</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Joza</surname> <given-names>N</given-names>
</name>
<name>
<surname>Tufi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Apetoh</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from &#x201c;silent&#x201d; to immunogenic</article-title>. <source>Cancer Res</source>. (<year>2007</year>) <volume>67</volume>:<page-range>7941&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1622</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obeid</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Panaretakis</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tufi</surname> <given-names>R</given-names>
</name>
<name>
<surname>Joza</surname> <given-names>N</given-names>
</name>
<name>
<surname>van Endert</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Ecto-calreticulin in immunogenic chemotherapy</article-title>. <source>Immunol Rev</source>. (<year>2007</year>) <volume>220</volume>:<fpage>22</fpage>&#x2013;<lpage>34</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1600-065X.2007.00567.x</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Obeid</surname> <given-names>M</given-names>
</name>
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ghiringhelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Fimia</surname> <given-names>GM</given-names>
</name>
<name>
<surname>Apetoh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Perfettini</surname> <given-names>JL</given-names>
</name>
<etal/>
</person-group>. <article-title>Calreticulin exposure dictates the immunogenicity of cancer cell death</article-title>. <source>Nat Med</source>. (<year>2007</year>) <volume>13</volume>:<fpage>54</fpage>&#x2013;<lpage>61</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm1523</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Krysko</surname> <given-names>DV</given-names>
</name>
<name>
<surname>Verfaillie</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kaczmarek</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ferreira</surname> <given-names>GB</given-names>
</name>
<name>
<surname>Marysael</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death</article-title>. <source>EMBO J</source>. (<year>2012</year>) <volume>31</volume>:<page-range>1062&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/emboj.2011.497</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoll</surname> <given-names>G</given-names>
</name>
<name>
<surname>Iribarren</surname> <given-names>K</given-names>
</name>
<name>
<surname>Michels</surname> <given-names>J</given-names>
</name>
<name>
<surname>Leary</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Cremer</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer</article-title>. <source>Oncoimmunology</source>. (<year>2016</year>) <volume>5</volume>:<elocation-id>e1177692</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2016.1177692</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fucikova</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kralikova</surname> <given-names>P</given-names>
</name>
<name>
<surname>Fialova</surname> <given-names>A</given-names>
</name>
<name>
<surname>Brtnicky</surname> <given-names>T</given-names>
</name>
<name>
<surname>Rob</surname> <given-names>L</given-names>
</name>
<name>
<surname>Bartunkova</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Human tumor cells killed by anthracyclines induce a tumor-specific immune response</article-title>. <source>Cancer Res</source>. (<year>2011</year>) <volume>71</volume>:<page-range>4821&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0950</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Asadzadeh</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Safarzadeh</surname> <given-names>E</given-names>
</name>
<name>
<surname>Safaei</surname> <given-names>S</given-names>
</name>
<name>
<surname>Baradaran</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mohammadi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hajiasgharzadeh</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Current approaches for combination therapy of cancer: the role of immunogenic cell death</article-title>. <source>Cancers (Basel)</source>. (<year>2020</year>) <volume>12</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.20944/preprints202003.0228.v1</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Murshid</surname> <given-names>A</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>J</given-names>
</name>
<name>
<surname>Calderwood</surname> <given-names>SK</given-names>
</name>
</person-group>. <article-title>The role of heat shock proteins in antigen cross presentation</article-title>. <source>Front Immunol</source>. (<year>2012</year>) <volume>3</volume>:<elocation-id>63</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2012.00063</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krysko</surname> <given-names>DV</given-names>
</name>
<name>
<surname>Garg</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Kaczmarek</surname> <given-names>A</given-names>
</name>
<name>
<surname>Krysko</surname> <given-names>O</given-names>
</name>
<name>
<surname>Agostinis</surname> <given-names>P</given-names>
</name>
<name>
<surname>Vandenabeele</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Immunogenic cell death and DAMPs in cancer therapy</article-title>. <source>Nat Rev Cancer</source>. (<year>2012</year>) <volume>12</volume>:<page-range>860&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc3380</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harding</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Benci</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Irianto</surname> <given-names>J</given-names>
</name>
<name>
<surname>Discher</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Minn</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Greenberg</surname> <given-names>RA</given-names>
</name>
</person-group>. <article-title>Mitotic progression following DNA damage enables pattern recognition within micronuclei</article-title>. <source>Nature</source>. (<year>2017</year>) <volume>548</volume>:<page-range>466&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature23470</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamazaki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kirchmair</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sato</surname> <given-names>A</given-names>
</name>
<name>
<surname>Buque</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rybstein</surname> <given-names>M</given-names>
</name>
<name>
<surname>Petroni</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Mitochondrial DNA drives abscopal responses to radiation that are inhibited by autophagy</article-title>. <source>Nat Immunol</source>. (<year>2020</year>) <volume>21</volume>:<page-range>1160&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41590-020-0751-0</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garg</surname> <given-names>AD</given-names>
</name>
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Apetoh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Baert</surname> <given-names>T</given-names>
</name>
<name>
<surname>Birge</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Bravo-San Pedro</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular and translational classifications of DAMPs in immunogenic cell death</article-title>. <source>Front Immunol</source>. (<year>2015</year>) <volume>6</volume>:<elocation-id>588</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2015.00588</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amarante-Mendes</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Adjemian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Branco</surname> <given-names>LM</given-names>
</name>
<name>
<surname>Zanetti</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Weinlich</surname> <given-names>R</given-names>
</name>
<name>
<surname>Bortoluci</surname> <given-names>KR</given-names>
</name>
</person-group>. <article-title>Pattern recognition receptors and the host cell death molecular machinery</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>2379</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.02379</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Decoding cell death signals in inflammation and immunity</article-title>. <source>Cell</source>. (<year>2010</year>) <volume>140</volume>:<fpage>798</fpage>&#x2013;<lpage>804</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2010.02.015</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiavoni</surname> <given-names>G</given-names>
</name>
<name>
<surname>Mattei</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gabriele</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Type I interferons as stimulators of DC-mediated cross-priming: impact on anti-tumor response</article-title>. <source>Front Immunol</source>. (<year>2013</year>) <volume>4</volume>:<elocation-id>483</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2013.00483</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Parker</surname> <given-names>BS</given-names>
</name>
<name>
<surname>Rautela</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hertzog</surname> <given-names>PJ</given-names>
</name>
</person-group>. <article-title>Antitumour actions of interferons: implications for cancer therapy</article-title>. <source>Nat Rev Cancer</source>. (<year>2016</year>) <volume>16</volume>:<page-range>131&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc.2016.14</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Schlemmer</surname> <given-names>F</given-names>
</name>
<name>
<surname>Boige</surname> <given-names>V</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Martins</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ghiringhelli</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunogenic death of colon cancer cells treated with oxaliplatin</article-title>. <source>Oncogene</source>. (<year>2010</year>) <volume>29</volume>:<page-range>482&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/onc.2009.356</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Humeau</surname> <given-names>J</given-names>
</name>
<name>
<surname>Levesque</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
<name>
<surname>Pol</surname> <given-names>JG</given-names>
</name>
</person-group>. <article-title>Gold standard assessment of immunogenic cell death in oncological mouse models</article-title>. <source>Methods Mol Biol</source>. (<year>2019</year>) <volume>1884</volume>:<fpage>297</fpage>&#x2013;<lpage>315</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-1-4939-8885-3_21</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Vitale</surname> <given-names>I</given-names>
</name>
<name>
<surname>Warren</surname> <given-names>S</given-names>
</name>
<name>
<surname>Adjemian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Agostinis</surname> <given-names>P</given-names>
</name>
<name>
<surname>Martinez</surname> <given-names>AB</given-names>
</name>
<etal/>
</person-group>. <article-title>Consensus guidelines for the definition, detection and interpretation of immunogenic cell death</article-title>. <source>J Immunother Cancer</source>. (<year>2020</year>) <volume>8</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jitc-2019-000337</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>West</surname> <given-names>NR</given-names>
</name>
<name>
<surname>Milne</surname> <given-names>K</given-names>
</name>
<name>
<surname>Truong</surname> <given-names>PT</given-names>
</name>
<name>
<surname>Macpherson</surname> <given-names>N</given-names>
</name>
<name>
<surname>Nelson</surname> <given-names>BH</given-names>
</name>
<name>
<surname>Watson</surname> <given-names>PH</given-names>
</name>
</person-group>. <article-title>Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer</article-title>. <source>Breast Cancer Res</source>. (<year>2011</year>) <volume>13</volume>:<fpage>R126</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/bcr3072</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halama</surname> <given-names>N</given-names>
</name>
<name>
<surname>Michel</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kloor</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zoernig</surname> <given-names>I</given-names>
</name>
<name>
<surname>Benner</surname> <given-names>A</given-names>
</name>
<name>
<surname>Spille</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy</article-title>. <source>Cancer Res</source>. (<year>2011</year>) <volume>71</volume>:<page-range>5670&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-0268</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Apetoh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ghiringhelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Obeid</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ortiz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Criollo</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy</article-title>. <source>Nat Med</source>. (<year>2007</year>) <volume>13</volume>:<page-range>1050&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm1622</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghiringhelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Apetoh</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tesniere</surname> <given-names>A</given-names>
</name>
<name>
<surname>Aymeric</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ortiz</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors</article-title>. <source>Nat Med</source>. (<year>2009</year>) <volume>15</volume>:<page-range>1170&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.2028</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname> <given-names>YD</given-names>
</name>
<name>
<surname>Quan</surname> <given-names>W</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Gan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JT</given-names>
</name>
<etal/>
</person-group>. <article-title>A bibliometric analysis of ferroptosis, necroptosis, pyroptosis, and cuproptosis in cancer from 2012 to 2022</article-title>. <source>Cell Death Discovery</source>. (<year>2023</year>) <volume>9</volume>:<fpage>129</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41420-023-01421-1</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Hua</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Ferroptosis, necroptosis, and pyroptosis in anticancer immunity</article-title>. <source>J Hematol Oncol</source>. (<year>2020</year>) <volume>13</volume>:<fpage>110</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13045-020-00946-7</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Degterev</surname> <given-names>A</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Boyce</surname> <given-names>M</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jagtap</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mizushima</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury</article-title>. <source>Nat Chem Biol</source>. (<year>2005</year>) <volume>1</volume>:<page-range>112&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nchembio711</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ray</surname> <given-names>CA</given-names>
</name>
<name>
<surname>Pickup</surname> <given-names>DJ</given-names>
</name>
</person-group>. <article-title>The mode of death of pig kidney cells infected with cowpox virus is governed by the expression of the crmA gene</article-title>. <source>Virology</source>. (<year>1996</year>) <volume>217</volume>:<page-range>384&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/viro.1996.0128</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vercammen</surname> <given-names>D</given-names>
</name>
<name>
<surname>Beyaert</surname> <given-names>R</given-names>
</name>
<name>
<surname>Denecker</surname> <given-names>G</given-names>
</name>
<name>
<surname>Goossens</surname> <given-names>V</given-names>
</name>
<name>
<surname>Van Loo</surname> <given-names>G</given-names>
</name>
<name>
<surname>Declercq</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor</article-title>. <source>J Exp Med</source>. (<year>1998</year>) <volume>187</volume>:<page-range>1477&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.187.9.1477</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newton</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wickliffe</surname> <given-names>KE</given-names>
</name>
<name>
<surname>Dugger</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Maltzman</surname> <given-names>A</given-names>
</name>
<name>
<surname>Roose-Girma</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dohse</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Cleavage of RIPK1 by caspase-8 is crucial for limiting apoptosis and necroptosis</article-title>. <source>Nature</source>. (<year>2019</year>) <volume>574</volume>:<page-range>428&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-019-1548-x</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fritsch</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gunther</surname> <given-names>SD</given-names>
</name>
<name>
<surname>Schwarzer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Albert</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Schorn</surname> <given-names>F</given-names>
</name>
<name>
<surname>Werthenbach</surname> <given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>Caspase-8 is the molecular switch for apoptosis, necroptosis and pyroptosis</article-title>. <source>Nature</source>. (<year>2019</year>) <volume>575</volume>:<page-range>683&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-019-1770-6</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Upton</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Kaiser</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Mocarski</surname> <given-names>ES</given-names>
</name>
</person-group>. <article-title>DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA</article-title>. <source>Cell Host Microbe</source>. (<year>2019</year>) <volume>26</volume>:<fpage>564</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.chom.2019.09.004</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wachsmuth</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kumari</surname> <given-names>S</given-names>
</name>
<name>
<surname>Schwarzer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>J</given-names>
</name>
<name>
<surname>Eren</surname> <given-names>RO</given-names>
</name>
<etal/>
</person-group>. <article-title>Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>580</volume>:<page-range>391&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-020-2129-8</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Decout</surname> <given-names>A</given-names>
</name>
<name>
<surname>Katz</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Venkatraman</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ablasser</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>The cGAS-STING pathway as a therapeutic target in inflammatory diseases</article-title>. <source>Nat Rev Immunol</source>. (<year>2021</year>) <volume>21</volume>:<page-range>548&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-021-00524-z</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ito</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Amin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ouchida</surname> <given-names>AT</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>359</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-017-00406-w</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laurien</surname> <given-names>L</given-names>
</name>
<name>
<surname>Nagata</surname> <given-names>M</given-names>
</name>
<name>
<surname>Schunke</surname> <given-names>H</given-names>
</name>
<name>
<surname>Delanghe</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wiederstein</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Kumari</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>1747</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-020-15466-8</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>He</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase</article-title>. <source>Cell</source>. (<year>2012</year>) <volume>148</volume>:<page-range>213&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2011.11.031</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raju</surname> <given-names>S</given-names>
</name>
<name>
<surname>Whalen</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Mengistu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Swanson</surname> <given-names>C</given-names>
</name>
<name>
<surname>Quinn</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>SS</given-names>
</name>
<etal/>
</person-group>. <article-title>Kinase domain dimerization drives RIPK3-dependent necroptosis</article-title>. <source>Sci Signal</source>. (<year>2018</year>) <volume>11</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/scisignal.aar2188</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Jitkaew</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chiang</surname> <given-names>HC</given-names>
</name>
<name>
<surname>Choksi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis</article-title>. <source>Nat Cell Biol</source>. (<year>2014</year>) <volume>16</volume>:<fpage>55</fpage>&#x2013;<lpage>65</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ncb2883</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Hoecke</surname> <given-names>L</given-names>
</name>
<name>
<surname>Van Lint</surname> <given-names>S</given-names>
</name>
<name>
<surname>Roose</surname> <given-names>K</given-names>
</name>
<name>
<surname>Van Parys</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vandenabeele</surname> <given-names>P</given-names>
</name>
<name>
<surname>Grooten</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes</article-title>. <source>Nat Commun</source>. (<year>2018</year>) <volume>9</volume>:<fpage>3417</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-018-05979-8</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snyder</surname> <given-names>AG</given-names>
</name>
<name>
<surname>Hubbard</surname> <given-names>NW</given-names>
</name>
<name>
<surname>Messmer</surname> <given-names>MN</given-names>
</name>
<name>
<surname>Kofman</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Hagan</surname> <given-names>CE</given-names>
</name>
<name>
<surname>Orozco</surname> <given-names>SL</given-names>
</name>
<etal/>
</person-group>. <article-title>Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity</article-title>. <source>Sci Immunol</source>. (<year>2019</year>) <volume>4</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/sciimmunol.aaw2004</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stoll</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Pro-necrotic molecules impact local immunosurveillance in human breast cancer</article-title>. <source>Oncoimmunology</source>. (<year>2017</year>) <volume>6</volume>:<elocation-id>e1299302</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2017.1299302</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer</article-title>. <source>Neoplasma</source>. (<year>2015</year>) <volume>62</volume>:<fpage>592</fpage>&#x2013;<lpage>601</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4149/neo_2015_071</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hockendorf</surname> <given-names>U</given-names>
</name>
<name>
<surname>Yabal</surname> <given-names>M</given-names>
</name>
<name>
<surname>Herold</surname> <given-names>T</given-names>
</name>
<name>
<surname>Munkhbaatar</surname> <given-names>E</given-names>
</name>
<name>
<surname>Rott</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jilg</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>RIPK3 restricts myeloid leukemogenesis by promoting cell death and differentiation of leukemia initiating cells</article-title>. <source>Cancer Cell</source>. (<year>2016</year>) <volume>30</volume>:<fpage>75</fpage>&#x2013;<lpage>91</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2016.06.002</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Geserick</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Schilling</surname> <given-names>R</given-names>
</name>
<name>
<surname>Horn</surname> <given-names>S</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Bertin</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Absence of RIPK3 predicts necroptosis resistance in Malignant melanoma</article-title>. <source>Cell Death Dis</source>. (<year>2015</year>) <volume>6</volume>:<fpage>e1884</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cddis.2015.240</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCormick</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Ghosh</surname> <given-names>A</given-names>
</name>
<name>
<surname>Trivedi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Coyne</surname> <given-names>CB</given-names>
</name>
<name>
<surname>Ferris</surname> <given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>Innate immune signaling through differential RIPK1 expression promote tumor progression in head and neck squamous cell carcinoma</article-title>. <source>Carcinogenesis</source>. (<year>2016</year>) <volume>37</volume>:<page-range>522&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/carcin/bgw032</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>M</given-names>
</name>
<name>
<surname>Shang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>EBV(LMP1)-induced metabolic reprogramming inhibits necroptosis through the hypermethylation of the RIP3 promoter</article-title>. <source>Theranostics</source>. (<year>2019</year>) <volume>9</volume>:<page-range>2424&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/thno.30941</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nicole</surname> <given-names>L</given-names>
</name>
<name>
<surname>Sanavia</surname> <given-names>T</given-names>
</name>
<name>
<surname>Cappellesso</surname> <given-names>R</given-names>
</name>
<name>
<surname>Maffeis</surname> <given-names>V</given-names>
</name>
<name>
<surname>Akiba</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kawahara</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Necroptosis-driving genes RIPK1, RIPK3 and MLKL-p are associated with intratumoral CD3(+) and CD8(+) T cell density and predict prognosis in hepatocellular carcinoma</article-title>. <source>J Immunother Cancer</source>. (<year>2022</year>) <volume>10</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jitc-2021-004031</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Werthmoller</surname> <given-names>N</given-names>
</name>
<name>
<surname>Frey</surname> <given-names>B</given-names>
</name>
<name>
<surname>Wunderlich</surname> <given-names>R</given-names>
</name>
<name>
<surname>Fietkau</surname> <given-names>R</given-names>
</name>
<name>
<surname>Gaipl</surname> <given-names>US</given-names>
</name>
</person-group>. <article-title>Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner</article-title>. <source>Cell Death Dis</source>. (<year>2015</year>) <volume>6</volume>:<elocation-id>e1761</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cddis.2015.129</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dixon</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Lemberg</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Lamprecht</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Skouta</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zaitsev</surname> <given-names>EM</given-names>
</name>
<name>
<surname>Gleason</surname> <given-names>CE</given-names>
</name>
<etal/>
</person-group>. <article-title>Ferroptosis: an iron-dependent form of nonapoptotic cell death</article-title>. <source>Cell</source>. (<year>2012</year>) <volume>149</volume>:<page-range>1060&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2012.03.042</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stockwell</surname> <given-names>BR</given-names>
</name>
</person-group>. <article-title>Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications</article-title>. <source>Cell</source>. (<year>2022</year>) <volume>185</volume>:<page-range>2401&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2022.06.003</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clement</surname> <given-names>CC</given-names>
</name>
<name>
<surname>Nanaware</surname> <given-names>PP</given-names>
</name>
<name>
<surname>Yamazaki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Negroni</surname> <given-names>MP</given-names>
</name>
<name>
<surname>Ramesh</surname> <given-names>K</given-names>
</name>
<name>
<surname>Morozova</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery</article-title>. <source>Immunity</source>. (<year>2021</year>) <volume>54</volume>:<fpage>721</fpage>&#x2013;<lpage>36 e10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2021.02.019</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Stockwell</surname> <given-names>BR</given-names>
</name>
<name>
<surname>Conrad</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Ferroptosis: mechanisms, biology and role in disease</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>266&#x2013;82</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41580-020-00324-8</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roh</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>EH</given-names>
</name>
<name>
<surname>Jang</surname> <given-names>HJ</given-names>
</name>
<name>
<surname>Park</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer</article-title>. <source>Cancer Lett</source>. (<year>2016</year>) <volume>381</volume>:<fpage>96</fpage>&#x2013;<lpage>103</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.canlet.2016.07.035</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Koppula</surname> <given-names>P</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>SH</given-names>
</name>
<etal/>
</person-group>. <article-title>The role of ferroptosis in ionizing radiation-induced cell death and tumor suppression</article-title>. <source>Cell Res</source>. (<year>2020</year>) <volume>30</volume>:<page-range>146&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41422-019-0263-3</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kepp</surname> <given-names>O</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Immunogenic cell death in radiation therapy</article-title>. <source>Oncoimmunology</source>. (<year>2013</year>) <volume>2</volume>:<fpage>e26536</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4161/onci.26536</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Efimova</surname> <given-names>I</given-names>
</name>
<name>
<surname>Catanzaro</surname> <given-names>E</given-names>
</name>
<name>
<surname>van der Meeren</surname> <given-names>L</given-names>
</name>
<name>
<surname>Turubanova</surname> <given-names>VD</given-names>
</name>
<name>
<surname>Hammad</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mishchenko</surname> <given-names>TA</given-names>
</name>
<etal/>
</person-group>. <article-title>Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity</article-title>. <source>J Immunother Cancer</source>. (<year>2020</year>) <volume>8</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jitc-2020-001369</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Recent progress in ferroptosis: inducers and inhibitors</article-title>. <source>Cell Death Discovery</source>. (<year>2022</year>) <volume>8</volume>:<fpage>501</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41420-022-01297-7</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lachaier</surname> <given-names>E</given-names>
</name>
<name>
<surname>Louandre</surname> <given-names>C</given-names>
</name>
<name>
<surname>Godin</surname> <given-names>C</given-names>
</name>
<name>
<surname>Saidak</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Baert</surname> <given-names>M</given-names>
</name>
<name>
<surname>Diouf</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors</article-title>. <source>Anticancer Res</source>. (<year>2014</year>) <volume>34</volume>:<page-range>6417&#x2013;22</page-range>.</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Understanding sorafenib-induced ferroptosis and resistance mechanisms: Implications for cancer therapy</article-title>. <source>Eur J Pharmacol</source>. (<year>2023</year>) <volume>955</volume>:<fpage>175913</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2023.175913</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>M</given-names>
</name>
<name>
<surname>Han</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Mechanism of sorafenib resistance associated with ferroptosis in HCC</article-title>. <source>Front Pharmacol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1207496</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2023.1207496</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Colic</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis</article-title>. <source>Nat Cell Biol</source>. (<year>2023</year>) <volume>25</volume>:<page-range>404&#x2013;14</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41556-023-01091-2</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhuang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gan</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Disulfidptosis: disulfide stress-induced cell death</article-title>. <source>Trends Cell Biol</source>. (<year>2023</year>) <volume>34</volume>:<page-range>327&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tcb.2023.07.009</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Olszewski</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lim</surname> <given-names>EW</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer</article-title>. <source>Nat Cell Biol</source>. (<year>2020</year>) <volume>22</volume>:<page-range>476&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41556-020-0496-x</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joly</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Delfarah</surname> <given-names>A</given-names>
</name>
<name>
<surname>Phung</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Parrish</surname> <given-names>S</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>NA</given-names>
</name>
</person-group>. <article-title>A synthetic lethal drug combination mimics glucose deprivation-induced cancer cell death in the presence of glucose</article-title>. <source>J Biol Chem</source>. (<year>2020</year>) <volume>295</volume>:<page-range>1350&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0021-9258(17)49891-7</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shin</surname> <given-names>CS</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>P</given-names>
</name>
<name>
<surname>Watrous</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Carelli</surname> <given-names>V</given-names>
</name>
<name>
<surname>D&#x2019;Aurelio</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jain</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>15074</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ncomms15074</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qi</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-associated genes in lung adenocarcinoma</article-title>. <source>Aging (Albany NY)</source>. (<year>2023</year>) <volume>15</volume>:<page-range>5075&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/aging.204782</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>XM</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>XM</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>SB</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>ZF</given-names>
</name>
</person-group>. <article-title>Identification of disulfidptosis-related genes with immune infiltration in hepatocellular carcinoma</article-title>. <source>Heliyon</source>. (<year>2023</year>) <volume>9</volume>:<fpage>e18436</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e18436</pub-id>
</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study</article-title>. <source>Med (Baltimore)</source>. (<year>2023</year>) <volume>102</volume>:<elocation-id>e35423</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MD.0000000000035423</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>D</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dian</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Le</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Molecular landmarks of tumor disulfidptosis across cancer types to promote disulfidptosis-target therapy</article-title>. <source>Redox Biol</source>. (<year>2023</year>) <volume>68</volume>:<fpage>102966</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.redox.2023.102966</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Song</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Han</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Lei</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeted inhibition of STAT3 induces immunogenic cell death of hepatocellular carcinoma cells via glycolysis</article-title>. <source>Mol Oncol</source>. (<year>2022</year>) <volume>16</volume>:<page-range>2861&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/1878-0261.13263</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsvetkov</surname> <given-names>P</given-names>
</name>
<name>
<surname>Coy</surname> <given-names>S</given-names>
</name>
<name>
<surname>Petrova</surname> <given-names>B</given-names>
</name>
<name>
<surname>Dreishpoon</surname> <given-names>M</given-names>
</name>
<name>
<surname>Verma</surname> <given-names>A</given-names>
</name>
<name>
<surname>Abdusamad</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Copper induces cell death by targeting lipoylated TCA cycle proteins</article-title>. <source>Science</source>. (<year>2022</year>) <volume>375</volume>:<page-range>1254&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.abf0529</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Cuproptosis: a copper-triggered modality of mitochondrial cell death</article-title>. <source>Cell Res</source>. (<year>2022</year>) <volume>32</volume>:<page-range>417&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41422-022-00653-7</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsvetkov</surname> <given-names>P</given-names>
</name>
<name>
<surname>Detappe</surname> <given-names>A</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>K</given-names>
</name>
<name>
<surname>Keys</surname> <given-names>HR</given-names>
</name>
<name>
<surname>Brune</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ying</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Mitochondrial metabolism promotes adaptation to proteotoxic stress</article-title>. <source>Nat Chem Biol</source>. (<year>2019</year>) <volume>15</volume>:<page-range>681&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41589-019-0291-9</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brewer</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Askari</surname> <given-names>F</given-names>
</name>
<name>
<surname>Dick</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Sitterly</surname> <given-names>J</given-names>
</name>
<name>
<surname>Fink</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Carlson</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Treatment of Wilson&#x2019;s disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine</article-title>. <source>Transl Res</source>. (<year>2009</year>) <volume>154</volume>:<page-range>70&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.trsl.2009.05.002</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Min</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Copper homeostasis and cuproptosis in health and disease</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2022</year>) <volume>7</volume>:<fpage>378</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-022-01229-y</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaur</surname> <given-names>P</given-names>
</name>
<name>
<surname>Johnson</surname> <given-names>A</given-names>
</name>
<name>
<surname>Northcote-Smith</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Suntharalingam</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Immunogenic cell death of breast cancer stem cells induced by an endoplasmic reticulum-targeting copper(II) complex</article-title>. <source>Chembiochem</source>. (<year>2020</year>) <volume>21</volume>:<page-range>3618&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cbic.202000553</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>HMGB1 is a mediator of cuproptosis-related sterile inflammation</article-title>. <source>Front Cell Dev Biol</source>. (<year>2022</year>) <volume>10</volume>:<elocation-id>996307</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcell.2022.996307</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagai</surname> <given-names>M</given-names>
</name>
<name>
<surname>Vo</surname> <given-names>NH</given-names>
</name>
<name>
<surname>Shin Ogawa</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chimmanamada</surname> <given-names>D</given-names>
</name>
<name>
<surname>Inoue</surname> <given-names>T</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells</article-title>. <source>Free Radic Biol Med</source>. (<year>2012</year>) <volume>52</volume>:<page-range>2142&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2012.03.017</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>SY</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>An enzyme-engineered nonporous copper(I) coordination polymer nanoplatform for cuproptosis-based synergistic cancer therapy</article-title>. <source>Adv Mater</source>. (<year>2022</year>) <volume>34</volume>:<elocation-id>e2204733</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/adma.202204733</pub-id>
</citation>
</ref>
<ref id="B98">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>An</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sverdlov</surname> <given-names>DY</given-names>
</name>
<name>
<surname>Vaid</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Miyamoto</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>2362</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-020-16092-0</pub-id>
</citation>
</ref>
<ref id="B99">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname> <given-names>CI</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Kiefer</surname> <given-names>RM</given-names>
</name>
<name>
<surname>Ralle</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gade</surname> <given-names>TP</given-names>
</name>
<name>
<surname>Brady</surname> <given-names>DC</given-names>
</name>
</person-group>. <article-title>Altered copper homeostasis underlies sensitivity of hepatocellular carcinoma to copper chelation</article-title>. <source>Metallomics</source>. (<year>2020</year>) <volume>12</volume>:<fpage>1995</fpage>&#x2013;<lpage>2008</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1039/d0mt00156b</pub-id>
</citation>
</ref>
<ref id="B100">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Voli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Valli</surname> <given-names>E</given-names>
</name>
<name>
<surname>Lerra</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kimpton</surname> <given-names>K</given-names>
</name>
<name>
<surname>Saletta</surname> <given-names>F</given-names>
</name>
<name>
<surname>Giorgi</surname> <given-names>FM</given-names>
</name>
<etal/>
</person-group>. <article-title>Intratumoral copper modulates PD-L1 expression and influences tumor immune evasion</article-title>. <source>Cancer Res</source>. (<year>2020</year>) <volume>80</volume>:<page-range>4129&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0471</pub-id>
</citation>
</ref>
<ref id="B101">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>L</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>F</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>A novel cuproptosis-related immune checkpoint gene signature identification and experimental validation in hepatocellular carcinoma</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>18514</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-022-22962-y</pub-id>
</citation>
</ref>
<ref id="B102">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Q</given-names>
</name>
</person-group>. <article-title>A prognostic signature of cuproptosis and TCA-related genes for hepatocellular carcinoma</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>1040736</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.1040736</pub-id>
</citation>
</ref>
<ref id="B103">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cong</surname> <given-names>T</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cuproptosis-related immune checkpoint gene signature: Prediction of prognosis and immune response for hepatocellular carcinoma</article-title>. <source>Front Genet</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1000997</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fgene.2022.1000997</pub-id>
</citation>
</ref>
<ref id="B104">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sperandio</surname> <given-names>S</given-names>
</name>
<name>
<surname>de Belle</surname> <given-names>I</given-names>
</name>
<name>
<surname>Bredesen</surname> <given-names>DE</given-names>
</name>
</person-group>. <article-title>An alternative, nonapoptotic form of programmed cell death</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2000</year>) <volume>97</volume>:<page-range>14376&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.97.26.14376</pub-id>
</citation>
</ref>
<ref id="B105">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>GN</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>XJ</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>DM</given-names>
</name>
<etal/>
</person-group>. <article-title>Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2022</year>) <volume>7</volume>:<fpage>317</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-022-01131-7</pub-id>
</citation>
</ref>
<ref id="B106">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gui</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>TNFRSF19 promotes endoplasmic reticulum stress-induced paraptosis via the activation of the MAPK pathway in triple-negative breast cancer cells</article-title>. <source>Cancer Gene Ther</source>. (<year>2023</year>) <volume>31</volume>:<page-range>217&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41417-023-00696-x</pub-id>
</citation>
</ref>
<ref id="B107">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mandula</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mohamed</surname> <given-names>E</given-names>
</name>
<name>
<surname>Jimenez</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sierra-Mondragon</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>DC</given-names>
</name>
<etal/>
</person-group>. <article-title>Ablation of the endoplasmic reticulum stress kinase PERK induces paraptosis and type I interferon to promote anti-tumor T cell responses</article-title>. <source>Cancer Cell</source>. (<year>2022</year>) <volume>40</volume>:<fpage>1145</fpage>&#x2013;<lpage>60 e9</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2022.08.016</pub-id>
</citation>
</ref>
<ref id="B108">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xue</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>C</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Morusin induces paraptosis-like cell death through mitochondrial calcium overload and dysfunction in epithelial ovarian cancer</article-title>. <source>Chem Biol Interact</source>. (<year>2018</year>) <volume>283</volume>:<fpage>59</fpage>&#x2013;<lpage>74</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cbi.2018.02.003</pub-id>
</citation>
</ref>
<ref id="B109">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pang</surname> <given-names>HF</given-names>
</name>
<name>
<surname>Li</surname> <given-names>XX</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Li</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Confirming whether novel rhein derivative 4a induces paraptosis-like cell death by endoplasmic reticulum stress in ovarian cancer cells</article-title>. <source>Eur J Pharmacol</source>. (<year>2020</year>) <volume>886</volume>:<fpage>173526</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173526</pub-id>
</citation>
</ref>
<ref id="B110">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munn</surname> <given-names>DH</given-names>
</name>
<name>
<surname>Mellor</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance</article-title>. <source>Trends Immunol</source>. (<year>2016</year>) <volume>37</volume>:<fpage>193</fpage>&#x2013;<lpage>207</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2016.01.002</pub-id>
</citation>
</ref>
<ref id="B111">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>RR</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>LP</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>ZX</given-names>
</name>
<etal/>
</person-group>. <article-title>Paraptosis inducer to effectively trigger immunogenic cell death for metastatic tumor immunotherapy with IDO inhibition</article-title>. <source>ACS Nano</source>. (<year>2023</year>) <volume>17</volume>:<page-range>9972&#x2013;86</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acsnano.2c11964</pub-id>
</citation>
</ref>
<ref id="B112">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andrabi</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Dawson</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Dawson</surname> <given-names>VL</given-names>
</name>
</person-group>. <article-title>Mitochondrial and nuclear cross talk in cell death: parthanatos</article-title>. <source>Ann N Y Acad Sci</source>. (<year>2008</year>) <volume>1147</volume>:<page-range>233&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1196/annals.1427.014</pub-id>
</citation>
</ref>
<ref id="B113">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>David</surname> <given-names>KK</given-names>
</name>
<name>
<surname>Andrabi</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Dawson</surname> <given-names>TM</given-names>
</name>
<name>
<surname>Dawson</surname> <given-names>VL</given-names>
</name>
</person-group>. <article-title>Parthanatos, a messenger of death</article-title>. <source>Front Biosci (Landmark Ed)</source>. (<year>2009</year>) <volume>14</volume>:<page-range>1116&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2741/3297</pub-id>
</citation>
</ref>
<ref id="B114">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dawson</surname> <given-names>VL</given-names>
</name>
<name>
<surname>Dawson</surname> <given-names>TM</given-names>
</name>
</person-group>. <article-title>Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos</article-title>. <source>Exp Neurol</source>. (<year>2009</year>) <volume>218</volume>:<fpage>193</fpage>&#x2013;<lpage>202</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.expneurol.2009.03.020</pub-id>
</citation>
</ref>
<ref id="B115">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>An</surname> <given-names>R</given-names>
</name>
<name>
<surname>Umanah</surname> <given-names>GK</given-names>
</name>
<name>
<surname>Park</surname> <given-names>H</given-names>
</name>
<name>
<surname>Nambiar</surname> <given-names>K</given-names>
</name>
<name>
<surname>Eacker</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1</article-title>. <source>Science</source>. (<year>2016</year>) <volume>354</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aad6872</pub-id>
</citation>
</ref>
<ref id="B116">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>N</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Han</surname> <given-names>G</given-names>
</name>
<name>
<surname>Ju</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in mice</article-title>. <source>Oncotarget</source>. (<year>2015</year>) <volume>6</volume>:<page-range>18445&#x2013;59</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/oncotarget.v6i21</pub-id>
</citation>
</ref>
<ref id="B117">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boulos</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Omer</surname> <given-names>EA</given-names>
</name>
<name>
<surname>Rigano</surname> <given-names>D</given-names>
</name>
<name>
<surname>Formisano</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chatterjee</surname> <given-names>M</given-names>
</name>
<name>
<surname>Leich</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Cynaropicrin disrupts tubulin and c-Myc-related signaling and induces parthanatos-type cell death in multiple myeloma</article-title>. <source>Acta Pharmacol Sin</source>. (<year>2023</year>) <volume>44</volume>:<page-range>2265&#x2013;81</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41401-023-01117-3</pub-id>
</citation>
</ref>
<ref id="B118">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of AKT induces p53/SIRT6/PARP1-dependent parthanatos to suppress tumor growth</article-title>. <source>Cell Commun Signal</source>. (<year>2022</year>) <volume>20</volume>:<fpage>93</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12964-022-00897-1</pub-id>
</citation>
</ref>
<ref id="B119">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kou</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Hasegawa</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Oxaliplatin induces the PARP1-mediated parthanatos in oral squamous cell carcinoma by increasing production of ROS</article-title>. <source>Aging (Albany NY)</source>. (<year>2021</year>) <volume>13</volume>:<page-range>4242&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/aging.v13i3</pub-id>
</citation>
</ref>
<ref id="B120">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maru</surname> <given-names>B</given-names>
</name>
<name>
<surname>Messikommer</surname> <given-names>A</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Seipel</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kovecses</surname> <given-names>O</given-names>
</name>
<name>
<surname>Valk</surname> <given-names>PJM</given-names>
</name>
<etal/>
</person-group>. <article-title>PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy</article-title>. <source>Cell Rep Med</source>. (<year>2023</year>) <volume>4</volume>:<fpage>101191</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101191</pub-id>
</citation>
</ref>
<ref id="B121">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Tao</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>A RIPK3-independent role of MLKL in suppressing parthanatos promotes immune evasion in hepatocellular carcinoma</article-title>. <source>Cell Discovery</source>. (<year>2023</year>) <volume>9</volume>:<fpage>7</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41421-022-00504-0</pub-id>
</citation>
</ref>
<ref id="B122">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>JTC801 induces pH-dependent death specifically in cancer cells and slows growth of tumors in mice</article-title>. <source>Gastroenterology</source>. (<year>2018</year>) <volume>154</volume>:<page-range>1480&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1053/j.gastro.2017.12.004</pub-id>
</citation>
</ref>
<ref id="B123">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kuang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Alkaliptosis: a new weapon for cancer therapy</article-title>. <source>Cancer Gene Ther</source>. (<year>2020</year>) <volume>27</volume>:<page-range>267&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41417-019-0134-6</pub-id>
</citation>
</ref>
<ref id="B124">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Mechanisms of alkaliptosis</article-title>. <source>Front Cell Dev Biol</source>. (<year>2023</year>) <volume>11</volume>:<elocation-id>1213995</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fcell.2023.1213995</pub-id>
</citation>
</ref>
<ref id="B125">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>ATP6V0D1 promotes alkaliptosis by blocking STAT3-mediated lysosomal pH homeostasis</article-title>. <source>Cell Rep</source>. (<year>2023</year>) <volume>42</volume>:<fpage>111911</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2022.111911</pub-id>
</citation>
</ref>
<ref id="B126">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>The acid gate in the lysosome</article-title>. <source>Autophagy</source>. (<year>2023</year>) <volume>19</volume>:<page-range>1368&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/15548627.2022.2125629</pub-id>
</citation>
</ref>
<ref id="B127">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swietach</surname> <given-names>P</given-names>
</name>
<name>
<surname>Vaughan-Jones</surname> <given-names>RD</given-names>
</name>
<name>
<surname>Harris</surname> <given-names>AL</given-names>
</name>
</person-group>. <article-title>Regulation of tumor pH and the role of carbonic anhydrase 9</article-title>. <source>Cancer Metastasis Rev</source>. (<year>2007</year>) <volume>26</volume>:<fpage>299</fpage>&#x2013;<lpage>310</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10555-007-9064-0</pub-id>
</citation>
</ref>
<ref id="B128">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>E</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>The HMGB1-AGER-STING1 pathway mediates the sterile inflammatory response to alkaliptosis</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2021</year>) <volume>560</volume>:<page-range>165&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2021.05.003</pub-id>
</citation>
</ref>
<ref id="B129">
<label>129</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Que</surname> <given-names>D</given-names>
</name>
<name>
<surname>Kuang</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>ACSS2-mediated NF-kappaB activation promotes alkaliptosis in human pancreatic cancer cells</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>1483</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-023-28261-4</pub-id>
</citation>
</ref>
<ref id="B130">
<label>130</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
<name>
<surname>Levine</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Autophagic cell death: the story of a misnomer</article-title>. <source>Nat Rev Mol Cell Biol</source>. (<year>2008</year>) <volume>9</volume>:<page-range>1004&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrm2529</pub-id>
</citation>
</ref>
<ref id="B131">
<label>131</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakahira</surname> <given-names>K</given-names>
</name>
<name>
<surname>Haspel</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Rathinam</surname> <given-names>VA</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Dolinay</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lam</surname> <given-names>HC</given-names>
</name>
<etal/>
</person-group>. <article-title>Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome</article-title>. <source>Nat Immunol</source>. (<year>2011</year>) <volume>12</volume>:<page-range>222&#x2013;30</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.1980</pub-id>
</citation>
</ref>
<ref id="B132">
<label>132</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jounai</surname> <given-names>N</given-names>
</name>
<name>
<surname>Takeshita</surname> <given-names>F</given-names>
</name>
<name>
<surname>Kobiyama</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sawano</surname> <given-names>A</given-names>
</name>
<name>
<surname>Miyawaki</surname> <given-names>A</given-names>
</name>
<name>
<surname>Xin</surname> <given-names>KQ</given-names>
</name>
<etal/>
</person-group>. <article-title>The Atg5 Atg12 conjugate associates with innate antiviral immune responses</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2007</year>) <volume>104</volume>:<page-range>14050&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0704014104</pub-id>
</citation>
</ref>
<ref id="B133">
<label>133</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saitoh</surname> <given-names>T</given-names>
</name>
<name>
<surname>Fujita</surname> <given-names>N</given-names>
</name>
<name>
<surname>Hayashi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Takahara</surname> <given-names>K</given-names>
</name>
<name>
<surname>Satoh</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Atg9a controls dsDNA-driven dynamic translocation of STING and the innate immune response</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2009</year>) <volume>106</volume>:<page-range>20842&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0911267106</pub-id>
</citation>
</ref>
<ref id="B134">
<label>134</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tal</surname> <given-names>MC</given-names>
</name>
<name>
<surname>Sasai</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>HK</given-names>
</name>
<name>
<surname>Yordy</surname> <given-names>B</given-names>
</name>
<name>
<surname>Shadel</surname> <given-names>GS</given-names>
</name>
<name>
<surname>Iwasaki</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2009</year>) <volume>106</volume>:<page-range>2770&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0807694106</pub-id>
</citation>
</ref>
<ref id="B135">
<label>135</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamamoto</surname> <given-names>K</given-names>
</name>
<name>
<surname>Venida</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yano</surname> <given-names>J</given-names>
</name>
<name>
<surname>Biancur</surname> <given-names>DE</given-names>
</name>
<name>
<surname>Kakiuchi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Gupta</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>581</volume>:<page-range>100&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-020-2229-5</pub-id>
</citation>
</ref>
<ref id="B136">
<label>136</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Kaer</surname> <given-names>L</given-names>
</name>
<name>
<surname>Parekh</surname> <given-names>VV</given-names>
</name>
<name>
<surname>Postoak</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Role of autophagy in MHC class I-restricted antigen presentation</article-title>. <source>Mol Immunol</source>. (<year>2019</year>) <volume>113</volume>:<fpage>2</fpage>&#x2013;<lpage>5</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.molimm.2017.10.021</pub-id>
</citation>
</ref>
<ref id="B137">
<label>137</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Sanchez-Lopez</surname> <given-names>E</given-names>
</name>
<name>
<surname>Karin</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Autophagy, inflammation, and immunity: A troika governing cancer and its treatment</article-title>. <source>Cell</source>. (<year>2016</year>) <volume>166</volume>:<page-range>288&#x2013;98</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2016.05.051</pub-id>
</citation>
</ref>
<ref id="B138">
<label>138</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1018903</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1018903</pub-id>
</citation>
</ref>
<ref id="B139">
<label>139</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zitvogel</surname> <given-names>L</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Autophagy and cellular immune responses</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>39</volume>:<page-range>211&#x2013;27</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.017</pub-id>
</citation>
</ref>
<ref id="B140">
<label>140</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Michaud</surname> <given-names>M</given-names>
</name>
<name>
<surname>Martins</surname> <given-names>I</given-names>
</name>
<name>
<surname>Sukkurwala</surname> <given-names>AQ</given-names>
</name>
<name>
<surname>Adjemian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Pellegatti</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice</article-title>. <source>Science</source>. (<year>2011</year>) <volume>334</volume>:<page-range>1573&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1208347</pub-id>
</citation>
</ref>
<ref id="B141">
<label>141</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins</surname> <given-names>I</given-names>
</name>
<name>
<surname>Michaud</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sukkurwala</surname> <given-names>AQ</given-names>
</name>
<name>
<surname>Adjemian</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death</article-title>. <source>Autophagy</source>. (<year>2012</year>) <volume>8</volume>:<page-range>413&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4161/auto.19009</pub-id>
</citation>
</ref>
<ref id="B142">
<label>142</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Basit</surname> <given-names>F</given-names>
</name>
<name>
<surname>Cristofanon</surname> <given-names>S</given-names>
</name>
<name>
<surname>Fulda</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Obatoclax (GX15&#x2013;070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes</article-title>. <source>Cell Death Differ</source>. (<year>2013</year>) <volume>20</volume>:<page-range>1161&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cdd.2013.45</pub-id>
</citation>
</ref>
<ref id="B143">
<label>143</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shoji-Kawata</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sumpter</surname> <given-names>RM</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Wei</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ginet</surname> <given-names>V</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia</article-title>. <source>Proc Natl Acad Sci U S A</source>. (<year>2013</year>) <volume>110</volume>:<page-range>20364&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1319661110</pub-id>
</citation>
</ref>
<ref id="B144">
<label>144</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Levine</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Autosis and autophagic cell death: the dark side of autophagy</article-title>. <source>Cell Death Differ</source>. (<year>2015</year>) <volume>22</volume>:<page-range>367&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cdd.2014.143</pub-id>
</citation>
</ref>
<ref id="B145">
<label>145</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shoji-Kawata</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sumpter</surname> <given-names>R</given-names>
</name>
<name>
<surname>Leveno</surname> <given-names>M</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>GR</given-names>
</name>
<name>
<surname>Zou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Kinch</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of a candidate therapeutic autophagy-inducing peptide</article-title>. <source>Nature</source>. (<year>2013</year>) <volume>494</volume>:<page-range>201&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature11866</pub-id>
</citation>
</ref>
<ref id="B146">
<label>146</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>N</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xue</surname> <given-names>G</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance</article-title>. <source>Cancer Cell</source>. (<year>2022</year>) <volume>40</volume>:<fpage>973</fpage>&#x2013;<lpage>85 e7</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2022.08.001</pub-id>
</citation>
</ref>
<ref id="B147">
<label>147</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galluzzi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Bravo-San Pedro</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Levine</surname> <given-names>B</given-names>
</name>
<name>
<surname>Green</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Kroemer</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles</article-title>. <source>Nat Rev Drug Discovery</source>. (<year>2017</year>) <volume>16</volume>:<fpage>487</fpage>&#x2013;<lpage>511</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrd.2017.22</pub-id>
</citation>
</ref>
<ref id="B148">
<label>148</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizushima</surname> <given-names>N</given-names>
</name>
<name>
<surname>Levine</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Autophagy in human diseases</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>383</volume>:<page-range>1564&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMra2022774</pub-id>
</citation>
</ref>
<ref id="B149">
<label>149</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cookson</surname> <given-names>BT</given-names>
</name>
<name>
<surname>Brennan</surname> <given-names>MA</given-names>
</name>
</person-group>. <article-title>Pro-inflammatory programmed cell death</article-title>. <source>Trends Microbiol</source>. (<year>2001</year>) <volume>9</volume>:<page-range>113&#x2013;4</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0966-842X(00)01936-3</pub-id>
</citation>
</ref>
<ref id="B150">
<label>150</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>H</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of pyroptosis in inflammation and cancer</article-title>. <source>Cell Mol Immunol</source>. (<year>2022</year>) <volume>19</volume>:<page-range>971&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41423-022-00905-x</pub-id>
</citation>
</ref>
<ref id="B151">
<label>151</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Pelegrin</surname> <given-names>P</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>The gasdermins, a protein family executing cell death and inflammation</article-title>. <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>20</volume>:<page-range>143&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-019-0228-2</pub-id>
</citation>
</ref>
<ref id="B152">
<label>152</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Dixit</surname> <given-names>VM</given-names>
</name>
</person-group>. <article-title>Inflammasomes: mechanism of assembly, regulation and signalling</article-title>. <source>Nat Rev Immunol</source>. (<year>2016</year>) <volume>16</volume>:<page-range>407&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri.2016.58</pub-id>
</citation>
</ref>
<ref id="B153">
<label>153</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swanson</surname> <given-names>KV</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ting</surname> <given-names>JP</given-names>
</name>
</person-group>. <article-title>The NLRP3 inflammasome: molecular activation and regulation to therapeutics</article-title>. <source>Nat Rev Immunol</source>. (<year>2019</year>) <volume>19</volume>:<page-range>477&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41577-019-0165-0</pub-id>
</citation>
</ref>
<ref id="B154">
<label>154</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelley</surname> <given-names>N</given-names>
</name>
<name>
<surname>Jeltema</surname> <given-names>D</given-names>
</name>
<name>
<surname>Duan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>The NLRP3 inflammasome: an overview of mechanisms of activation and regulation</article-title>. <source>Int J Mol Sci</source>. (<year>2019</year>) <volume>20</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/ijms20133328</pub-id>
</citation>
</ref>
<ref id="B155">
<label>155</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandes-Alnemri</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Datta</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Alnemri</surname> <given-names>ES</given-names>
</name>
</person-group>. <article-title>AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA</article-title>. <source>Nature</source>. (<year>2009</year>) <volume>458</volume>:<page-range>509&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature07710</pub-id>
</citation>
</ref>
<ref id="B156">
<label>156</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hornung</surname> <given-names>V</given-names>
</name>
<name>
<surname>Ablasser</surname> <given-names>A</given-names>
</name>
<name>
<surname>Charrel-Dennis</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bauernfeind</surname> <given-names>F</given-names>
</name>
<name>
<surname>Horvath</surname> <given-names>G</given-names>
</name>
<name>
<surname>Caffrey</surname> <given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC</article-title>. <source>Nature</source>. (<year>2009</year>) <volume>458</volume>:<page-range>514&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature07725</pub-id>
</citation>
</ref>
<ref id="B157">
<label>157</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Ruan</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Magupalli</surname> <given-names>VG</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores</article-title>. <source>Nature</source>. (<year>2016</year>) <volume>535</volume>:<page-range>153&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature18629</pub-id>
</citation>
</ref>
<ref id="B158">
<label>158</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title>. <source>Nature</source>. (<year>2015</year>) <volume>526</volume>:<page-range>660&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature15514</pub-id>
</citation>
</ref>
<ref id="B159">
<label>159</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Magupalli</surname> <given-names>VG</given-names>
</name>
<name>
<surname>Pablo</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Vora</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Gasdermin D pore structure reveals preferential release of mature interleukin-1</article-title>. <source>Nature</source>. (<year>2021</year>) <volume>593</volume>:<page-range>607&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-021-03478-3</pub-id>
</citation>
</ref>
<ref id="B160">
<label>160</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayagaki</surname> <given-names>N</given-names>
</name>
<name>
<surname>Warming</surname> <given-names>S</given-names>
</name>
<name>
<surname>Lamkanfi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Vande Walle</surname> <given-names>L</given-names>
</name>
<name>
<surname>Louie</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Non-canonical inflammasome activation targets caspase-11</article-title>. <source>Nature</source>. (<year>2011</year>) <volume>479</volume>:<page-range>117&#x2013;21</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature10558</pub-id>
</citation>
</ref>
<ref id="B161">
<label>161</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayagaki</surname> <given-names>N</given-names>
</name>
<name>
<surname>Stowe</surname> <given-names>IB</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>BL</given-names>
</name>
<name>
<surname>O&#x2019;Rourke</surname> <given-names>K</given-names>
</name>
<name>
<surname>Anderson</surname> <given-names>K</given-names>
</name>
<name>
<surname>Warming</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling</article-title>. <source>Nature</source>. (<year>2015</year>) <volume>526</volume>:<page-range>666&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature15541</pub-id>
</citation>
</ref>
<ref id="B162">
<label>162</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kayagaki</surname> <given-names>N</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>MT</given-names>
</name>
<name>
<surname>Stowe</surname> <given-names>IB</given-names>
</name>
<name>
<surname>Ramani</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Gonzalez</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Akashi-Takamura</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Noncanonical inflammasome activation by intracellular LPS independent of TLR4</article-title>. <source>Science</source>. (<year>2013</year>) <volume>341</volume>:<page-range>1246&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1240248</pub-id>
</citation>
</ref>
<ref id="B163">
<label>163</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hagar</surname> <given-names>JA</given-names>
</name>
<name>
<surname>Powell</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Aachoui</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ernst</surname> <given-names>RK</given-names>
</name>
<name>
<surname>Miao</surname> <given-names>EA</given-names>
</name>
</person-group>. <article-title>Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock</article-title>. <source>Science</source>. (<year>2013</year>) <volume>341</volume>:<page-range>1250&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1240988</pub-id>
</citation>
</ref>
<ref id="B164">
<label>164</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammatory caspases are innate immune receptors for intracellular LPS</article-title>. <source>Nature</source>. (<year>2014</year>) <volume>514</volume>:<page-range>187&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature13683</pub-id>
</citation>
</ref>
<ref id="B165">
<label>165</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baker</surname> <given-names>PJ</given-names>
</name>
<name>
<surname>Boucher</surname> <given-names>D</given-names>
</name>
<name>
<surname>Bierschenk</surname> <given-names>D</given-names>
</name>
<name>
<surname>Tebartz</surname> <given-names>C</given-names>
</name>
<name>
<surname>Whitney</surname> <given-names>PG</given-names>
</name>
<name>
<surname>D&#x2019;Silva</surname> <given-names>DB</given-names>
</name>
<etal/>
</person-group>. <article-title>NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5</article-title>. <source>Eur J Immunol</source>. (<year>2015</year>) <volume>45</volume>:<page-range>2918&#x2013;26</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.201545655</pub-id>
</citation>
</ref>
<ref id="B166">
<label>166</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaidt</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Hornung</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>Pore formation by GSDMD is the effector mechanism of pyroptosis</article-title>. <source>EMBO J</source>. (<year>2016</year>) <volume>35</volume>:<page-range>2167&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.15252/embj.201695415</pub-id>
</citation>
</ref>
<ref id="B167">
<label>167</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sborgi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ruhl</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mulvihill</surname> <given-names>E</given-names>
</name>
<name>
<surname>Pipercevic</surname> <given-names>J</given-names>
</name>
<name>
<surname>Heilig</surname> <given-names>R</given-names>
</name>
<name>
<surname>Stahlberg</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death</article-title>. <source>EMBO J</source>. (<year>2016</year>) <volume>35</volume>:<page-range>1766&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.15252/embj.201694696</pub-id>
</citation>
</ref>
<ref id="B168">
<label>168</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Gasdermin E suppresses tumour growth by activating anti-tumour immunity</article-title>. <source>Nature</source>. (<year>2020</year>) <volume>579</volume>:<page-range>415&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41586-020-2071-9</pub-id>
</citation>
</ref>
<ref id="B169">
<label>169</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>W</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>W</given-names>
</name>
<name>
<surname>He</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin</article-title>. <source>Nature</source>. (<year>2017</year>) <volume>547</volume>:<fpage>99</fpage>&#x2013;<lpage>103</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature22393</pub-id>
</citation>
</ref>
<ref id="B170">
<label>170</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogers</surname> <given-names>C</given-names>
</name>
<name>
<surname>Fernandes-Alnemri</surname> <given-names>T</given-names>
</name>
<name>
<surname>Mayes</surname> <given-names>L</given-names>
</name>
<name>
<surname>Alnemri</surname> <given-names>D</given-names>
</name>
<name>
<surname>Cingolani</surname> <given-names>G</given-names>
</name>
<name>
<surname>Alnemri</surname> <given-names>ES</given-names>
</name>
</person-group>. <article-title>Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death</article-title>. <source>Nat Commun</source>. (<year>2017</year>) <volume>8</volume>:<fpage>14128</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ncomms14128</pub-id>
</citation>
</ref>
<ref id="B171">
<label>171</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Erkes</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>W</given-names>
</name>
<name>
<surname>Sanchez</surname> <given-names>IM</given-names>
</name>
<name>
<surname>Purwin</surname> <given-names>TJ</given-names>
</name>
<name>
<surname>Rogers</surname> <given-names>C</given-names>
</name>
<name>
<surname>Field</surname> <given-names>CO</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutant BRAF and MEK inhibitors regulate the tumor immune microenvironment via pyroptosis</article-title>. <source>Cancer Discovery</source>. (<year>2020</year>) <volume>10</volume>:<page-range>254&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0672</pub-id>
</citation>
</ref>
<ref id="B172">
<label>172</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hossain</surname> <given-names>DMS</given-names>
</name>
<name>
<surname>Javaid</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Sawant</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hinton</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression</article-title>. <source>J Clin Invest</source>. (<year>2018</year>) <volume>128</volume>:<page-range>644&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI94586</pub-id>
</citation>
</ref>
<ref id="B173">
<label>173</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>D</given-names>
</name>
<name>
<surname>Du</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Cyclin-dependent kinase inhibitors function as potential immune regulators via inducing pyroptosis in triple negative breast cancer</article-title>. <source>Front Oncol</source>. (<year>2022</year>) <volume>12</volume>:<elocation-id>820696</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.820696</pub-id>
</citation>
</ref>
<ref id="B174">
<label>174</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akino</surname> <given-names>K</given-names>
</name>
<name>
<surname>Toyota</surname> <given-names>M</given-names>
</name>
<name>
<surname>Suzuki</surname> <given-names>H</given-names>
</name>
<name>
<surname>Imai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Maruyama</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kusano</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer</article-title>. <source>Cancer Sci</source>. (<year>2007</year>) <volume>98</volume>:<fpage>88</fpage>&#x2013;<lpage>95</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1349-7006.2006.00351.x</pub-id>
</citation>
</ref>
<ref id="B175">
<label>175</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yamashita</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nagpal</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Baek</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinoma</article-title>. <source>Oncogene</source>. (<year>2008</year>) <volume>27</volume>:<page-range>3624&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/sj.onc.1211021</pub-id>
</citation>
</ref>
<ref id="B176">
<label>176</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>ZZ</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>SW</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>BX</given-names>
</name>
<etal/>
</person-group>. <article-title>GSDME is related to prognosis and response to chemotherapy in oral cancer</article-title>. <source>J Dent Res</source>. (<year>2022</year>) <volume>101</volume>:<page-range>848&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/00220345211073072</pub-id>
</citation>
</ref>
<ref id="B177">
<label>177</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname> <given-names>Z</given-names>
</name>
<name>
<surname>He</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Su</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells</article-title>. <source>Science</source>. (<year>2020</year>) <volume>368</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.aaz7548</pub-id>
</citation>
</ref>
<ref id="B178">
<label>178</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Darmon</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Nicholson</surname> <given-names>DW</given-names>
</name>
<name>
<surname>Bleackley</surname> <given-names>RC</given-names>
</name>
</person-group>. <article-title>Activation of the apoptotic protease CPP32 by cytotoxic T-cell-derived granzyme B</article-title>. <source>Nature</source>. (<year>1995</year>) <volume>377</volume>:<page-range>446&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/377446a0</pub-id>
</citation>
</ref>
<ref id="B179">
<label>179</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chowdhury</surname> <given-names>D</given-names>
</name>
<name>
<surname>Lieberman</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Death by a thousand cuts: granzyme pathways of programmed cell death</article-title>. <source>Annu Rev Immunol</source>. (<year>2008</year>) <volume>26</volume>:<fpage>389</fpage>&#x2013;<lpage>420</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090404</pub-id>
</citation>
</ref>
<ref id="B180">
<label>180</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burnette</surname> <given-names>BC</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chlewicki</surname> <given-names>L</given-names>
</name>
<name>
<surname>Khodarev</surname> <given-names>NN</given-names>
</name>
<name>
<surname>Weichselbaum</surname> <given-names>RR</given-names>
</name>
<etal/>
</person-group>. <article-title>The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity</article-title>. <source>Cancer Res</source>. (<year>2011</year>) <volume>71</volume>:<page-range>2488&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2820</pub-id>
</citation>
</ref>
<ref id="B181">
<label>181</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sistigu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Yamazaki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Vacchelli</surname> <given-names>E</given-names>
</name>
<name>
<surname>Chaba</surname> <given-names>K</given-names>
</name>
<name>
<surname>Enot</surname> <given-names>DP</given-names>
</name>
<name>
<surname>Adam</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy</article-title>. <source>Nat Med</source>. (<year>2014</year>) <volume>20</volume>:<page-range>1301&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.3708</pub-id>
</citation>
</ref>
<ref id="B182">
<label>182</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingram</surname> <given-names>JP</given-names>
</name>
<name>
<surname>Thapa</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Fisher</surname> <given-names>A</given-names>
</name>
<name>
<surname>Tummers</surname> <given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>ZBP1/DAI drives RIPK3-mediated cell death induced by IFNs in the absence of RIPK1</article-title>. <source>J Immunol</source>. (<year>2019</year>) <volume>203</volume>:<page-range>1348&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1900216</pub-id>
</citation>
</ref>
<ref id="B183">
<label>183</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duewell</surname> <given-names>P</given-names>
</name>
<name>
<surname>Steger</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lohr</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bourhis</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hoelz</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kirchleitner</surname> <given-names>SV</given-names>
</name>
<etal/>
</person-group>. <article-title>RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells</article-title>. <source>Cell Death Differ</source>. (<year>2014</year>) <volume>21</volume>:<page-range>1825&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cdd.2014.96</pub-id>
</citation>
</ref>
<ref id="B184">
<label>184</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arimoto</surname> <given-names>KI</given-names>
</name>
<name>
<surname>Miyauchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Stoner</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>DE</given-names>
</name>
</person-group>. <article-title>Negative regulation of type I IFN signaling</article-title>. <source>J Leukoc Biol</source>. (<year>2018</year>) <volume>103</volume>:<page-range>1099&#x2013;116</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/JLB.2MIR0817-342R</pub-id>
</citation>
</ref>
<ref id="B185">
<label>185</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arimoto</surname> <given-names>KI</given-names>
</name>
<name>
<surname>Lochte</surname> <given-names>S</given-names>
</name>
<name>
<surname>Stoner</surname> <given-names>SA</given-names>
</name>
<name>
<surname>Burkart</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Miyauchi</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling</article-title>. <source>Nat Struct Mol Biol</source>. (<year>2017</year>) <volume>24</volume>:<page-range>279&#x2013;89</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nsmb.3378</pub-id>
</citation>
</ref>
<ref id="B186">
<label>186</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arimoto</surname> <given-names>KI</given-names>
</name>
<name>
<surname>Miyauchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Troutman</surname> <given-names>TD</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Stoner</surname> <given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>Expansion of interferon inducible gene pool via USP18 inhibition promotes cancer cell pyroptosis</article-title>. <source>Nat Commun</source>. (<year>2023</year>) <volume>14</volume>:<fpage>251</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-022-35348-5</pub-id>
</citation>
</ref>
<ref id="B187">
<label>187</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meuwissen</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Schot</surname> <given-names>R</given-names>
</name>
<name>
<surname>Buta</surname> <given-names>S</given-names>
</name>
<name>
<surname>Oudesluijs</surname> <given-names>G</given-names>
</name>
<name>
<surname>Tinschert</surname> <given-names>S</given-names>
</name>
<name>
<surname>Speer</surname> <given-names>SD</given-names>
</name>
<etal/>
</person-group>. <article-title>Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome</article-title>. <source>J Exp Med</source>. (<year>2016</year>) <volume>213</volume>:<page-range>1163&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20151529</pub-id>
</citation>
</ref>
<ref id="B188">
<label>188</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alsohime</surname> <given-names>F</given-names>
</name>
<name>
<surname>Martin-Fernandez</surname> <given-names>M</given-names>
</name>
<name>
<surname>Temsah</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Alabdulhafid</surname> <given-names>M</given-names>
</name>
<name>
<surname>Le Voyer</surname> <given-names>T</given-names>
</name>
<name>
<surname>Alghamdi</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>JAK inhibitor therapy in a child with inherited USP18 deficiency</article-title>. <source>N Engl J Med</source>. (<year>2020</year>) <volume>382</volume>:<page-range>256&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1905633</pub-id>
</citation>
</ref>
<ref id="B189">
<label>189</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyauchi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Arimoto</surname> <given-names>KI</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>DE</given-names>
</name>
</person-group>. <article-title>Reprogramming of tumor-associated macrophages via NEDD4-mediated CSF1R degradation by targeting USP18</article-title>. <source>Cell Rep</source>. (<year>2023</year>) <volume>42</volume>:<fpage>113560</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2023.113560</pub-id>
</citation>
</ref>
<ref id="B190">
<label>190</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Duve</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Lysosomes revisited</article-title>. <source>Eur J Biochem</source>. (<year>1983</year>) <volume>137</volume>:<page-range>391&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1432-1033.1983.tb07841.x</pub-id>
</citation>
</ref>
<ref id="B191">
<label>191</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Franko</surname> <given-names>J</given-names>
</name>
<name>
<surname>Pomfy</surname> <given-names>M</given-names>
</name>
<name>
<surname>Prosbova</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>Apoptosis and cell death (mechanisms, pharmacology and promise for the future)</article-title>. <source>Acta Med (Hradec Kralove)</source>. (<year>2000</year>) <volume>43</volume>:<page-range>63&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.14712/18059694.2019.115</pub-id>
</citation>
</ref>
<ref id="B192">
<label>192</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bruchard</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mignot</surname> <given-names>G</given-names>
</name>
<name>
<surname>Derangere</surname> <given-names>V</given-names>
</name>
<name>
<surname>Chalmin</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chevriaux</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vegran</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth</article-title>. <source>Nat Med</source>. (<year>2013</year>) <volume>19</volume>:<fpage>57</fpage>&#x2013;<lpage>64</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.2999</pub-id>
</citation>
</ref>
<ref id="B193">
<label>193</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgener</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Leborgne</surname> <given-names>NGF</given-names>
</name>
<name>
<surname>Snipas</surname> <given-names>SJ</given-names>
</name>
<name>
<surname>Salvesen</surname> <given-names>GS</given-names>
</name>
<name>
<surname>Bird</surname> <given-names>PI</given-names>
</name>
<name>
<surname>Benarafa</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Cathepsin G inhibition by serpinb1 and serpinb6 prevents programmed necrosis in neutrophils and monocytes and reduces GSDMD-driven inflammation</article-title>. <source>Cell Rep</source>. (<year>2019</year>) <volume>27</volume>:<fpage>3646</fpage>&#x2013;<lpage>56 e5</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2019.05.065</pub-id>
</citation>
</ref>
<ref id="B194">
<label>194</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Choi</surname> <given-names>HMC</given-names>
</name>
<name>
<surname>Sarkar</surname> <given-names>C</given-names>
</name>
<name>
<surname>Koh</surname> <given-names>EY</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Lysosomal damage after spinal cord injury causes accumulation of RIPK1 and RIPK3 proteins and potentiation of necroptosis</article-title>. <source>Cell Death Dis</source>. (<year>2018</year>) <volume>9</volume>:<fpage>476</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41419-018-0469-1</pub-id>
</citation>
</ref>
<ref id="B195">
<label>195</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torii</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shintoku</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kubota</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yaegashi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Torii</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sasaki</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>An essential role for functional lysosomes in ferroptosis of cancer cells</article-title>. <source>Biochem J</source>. (<year>2016</year>) <volume>473</volume>:<page-range>769&#x2013;77</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/BJ20150658</pub-id>
</citation>
</ref>
<ref id="B196">
<label>196</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname> <given-names>H</given-names>
</name>
<name>
<surname>Bai</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Jia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Ferroptosis is a lysosomal cell death process</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2018</year>) <volume>503</volume>:<page-range>1550&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2018.07.078</pub-id>
</citation>
</ref>
<ref id="B197">
<label>197</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kawai</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tsuchida</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kozaki</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tanaka</surname> <given-names>H</given-names>
</name>
<name>
<surname>Shin</surname> <given-names>KS</given-names>
</name>
<etal/>
</person-group>. <article-title>Poly IC triggers a cathepsin D- and IPS-1-dependent pathway to enhance cytokine production and mediate dendritic cell necroptosis</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>38</volume>:<page-range>717&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2012.12.007</pub-id>
</citation>
</ref>
<ref id="B198">
<label>198</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhardwaj</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Versace</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Harper</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Goldman</surname> <given-names>AR</given-names>
</name>
<name>
<surname>Crissey</surname> <given-names>MAS</given-names>
</name>
<etal/>
</person-group>. <article-title>Lysosomal lipid peroxidation regulates tumor immunity</article-title>. <source>J Clin Invest</source>. (<year>2023</year>) <volume>133</volume>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI164596</pub-id>
</citation>
</ref>
<ref id="B199">
<label>199</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pfirschke</surname> <given-names>C</given-names>
</name>
<name>
<surname>Engblom</surname> <given-names>C</given-names>
</name>
<name>
<surname>Rickelt</surname> <given-names>S</given-names>
</name>
<name>
<surname>Cortez-Retamozo</surname> <given-names>V</given-names>
</name>
<name>
<surname>Garris</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pucci</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy</article-title>. <source>Immunity</source>. (<year>2016</year>) <volume>44</volume>:<page-range>343&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2015.11.024</pub-id>
</citation>
</ref>
<ref id="B200">
<label>200</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sprooten</surname> <given-names>J</given-names>
</name>
<name>
<surname>Laureano</surname> <given-names>RS</given-names>
</name>
<name>
<surname>Vanmeerbeek</surname> <given-names>I</given-names>
</name>
<name>
<surname>Govaerts</surname> <given-names>J</given-names>
</name>
<name>
<surname>Naulaerts</surname> <given-names>S</given-names>
</name>
<name>
<surname>Borras</surname> <given-names>DM</given-names>
</name>
<etal/>
</person-group>. <article-title>Trial watch: chemotherapy-induced immunogenic cell death in oncology</article-title>. <source>Oncoimmunology</source>. (<year>2023</year>) <volume>12</volume>:<fpage>2219591</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2023.2219591</pub-id>
</citation>
</ref>
<ref id="B201">
<label>201</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shao</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Li</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>The role of necroptosis in disease and treatment</article-title>. <source>MedComm (2020)</source>. (<year>2021</year>) <volume>2</volume>:<page-range>730&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/mco2.108</pub-id>
</citation>
</ref>
<ref id="B202">
<label>202</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sheng</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Targeting necroptosis in anticancer therapy: mechanisms and modulators</article-title>. <source>Acta Pharm Sin B</source>. (<year>2020</year>) <volume>10</volume>:<page-range>1601&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.apsb.2020.01.007</pub-id>
</citation>
</ref>
<ref id="B203">
<label>203</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hanson</surname> <given-names>S</given-names>
</name>
<name>
<surname>Dharan</surname> <given-names>A</given-names>
</name>
<name>
<surname>P</surname> <given-names>VS</given-names>
</name>
<name>
<surname>Pal</surname> <given-names>S</given-names>
</name>
<name>
<surname>Nair</surname> <given-names>BG</given-names>
</name>
<name>
<surname>Kar</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Paraptosis: a unique cell death mode for targeting cancer</article-title>. <source>Front Pharmacol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1159409</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphar.2023.1159409</pub-id>
</citation>
</ref>
<ref id="B204">
<label>204</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>K</given-names>
</name>
<name>
<surname>Riegman</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ingold</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Ultrasmall nanoparticles induce ferroptosis in nutrient-deprived cancer cells and suppress tumour growth</article-title>. <source>Nat Nanotechnol</source>. (<year>2016</year>) <volume>11</volume>:<page-range>977&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nnano.2016.164</pub-id>
</citation>
</ref>
<ref id="B205">
<label>205</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Vacancies on 2D transition metal dichalcogenides elicit ferroptotic cell death</article-title>. <source>Nat Commun</source>. (<year>2020</year>) <volume>11</volume>:<fpage>3484</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-020-17300-7</pub-id>
</citation>
</ref>
<ref id="B206">
<label>206</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Pi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>F</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA</article-title>. <source>J Nanobiotechnology</source>. (<year>2023</year>) <volume>21</volume>:<fpage>360</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12951-023-02067-y</pub-id>
</citation>
</ref>
</ref-list>
<glossary>
<title>Glossary</title>
<table-wrap position="anchor">
<table frame="hsides">
<tbody>
<tr>
<td valign="top" align="left">ICB</td>
<td valign="top" align="left">immune checkpoint blockade</td>
</tr>
<tr>
<td valign="top" align="left">ICD</td>
<td valign="top" align="left">immunogenic cell death</td>
</tr>
<tr>
<td valign="top" align="left">RCD</td>
<td valign="top" align="left">regulated cell death</td>
</tr>
<tr>
<td valign="top" align="left">PLK2</td>
<td valign="top" align="left">polo like kinase 2</td>
</tr>
<tr>
<td valign="top" align="left">TME</td>
<td valign="top" align="left">tumor microenvironment</td>
</tr>
<tr>
<td valign="top" align="left">TGF-&#x3b2;</td>
<td valign="top" align="left">transforming growth factor-&#x3b2;</td>
</tr>
<tr>
<td valign="top" align="left">DAMPs</td>
<td valign="top" align="left">damage-associated molecular patterns</td>
</tr>
<tr>
<td valign="top" align="left">cDAMPs</td>
<td valign="top" align="left">constitutive DAMPs</td>
</tr>
<tr>
<td valign="top" align="left">iDAMPs</td>
<td valign="top" align="left">inducible DAMPs</td>
</tr>
<tr>
<td valign="top" align="left">CXCL10</td>
<td valign="top" align="left">C-X-C motif chemokine ligand 10</td>
</tr>
<tr>
<td valign="top" align="left">PAMPs</td>
<td valign="top" align="left">pathogen-associated molecular patterns</td>
</tr>
<tr>
<td valign="top" align="left">HMGB1</td>
<td valign="top" align="left">nuclear protein high mobility group box 1</td>
</tr>
<tr>
<td valign="top" align="left">ATP</td>
<td valign="top" align="left">adenosine triphosphate</td>
</tr>
<tr>
<td valign="top" align="left">APC</td>
<td valign="top" align="left">antigen-presenting cell</td>
</tr>
<tr>
<td valign="top" align="left">DC</td>
<td valign="top" align="left">dendritic cell</td>
</tr>
<tr>
<td valign="top" align="left">TLR</td>
<td valign="top" align="left">toll-like receptor</td>
</tr>
<tr>
<td valign="top" align="left">RAGE</td>
<td valign="top" align="left">receptors for advanced glycation end-products</td>
</tr>
<tr>
<td valign="top" align="left">IL-1 b</td>
<td valign="top" align="left">interleukin 1b</td>
</tr>
<tr>
<td valign="top" align="left">CTL</td>
<td valign="top" align="left">cytotoxic T lymphocyte</td>
</tr>
<tr>
<td valign="top" align="left">CRT</td>
<td valign="top" align="left">calreticulin</td>
</tr>
<tr>
<td valign="top" align="left">MHC</td>
<td valign="top" align="left">major histocompatibility complex</td>
</tr>
<tr>
<td valign="top" align="left">AIM2</td>
<td valign="top" align="left">absent in melanoma 2</td>
</tr>
<tr>
<td valign="top" align="left">NK</td>
<td valign="top" align="left">natural killer</td>
</tr>
<tr>
<td valign="top" align="left">LCD</td>
<td valign="top" align="left">lysosomal cell death</td>
</tr>
<tr>
<td valign="top" align="left">ACD</td>
<td valign="top" align="left">accidental cell death</td>
</tr>
<tr>
<td valign="top" align="left">CrmA</td>
<td valign="top" align="left">cytokine response modifier A</td>
</tr>
<tr>
<td valign="top" align="left">TNF&#x3b1;</td>
<td valign="top" align="left">tumor necrosis factor-&#x3b1;</td>
</tr>
<tr>
<td valign="top" align="left">TRAIL</td>
<td valign="top" align="left">TNF-related apoptosis-inducing ligand</td>
</tr>
<tr>
<td valign="top" align="left">FADD</td>
<td valign="top" align="left">fas-associated via death domain</td>
</tr>
<tr>
<td valign="top" align="left">PRR</td>
<td valign="top" align="left">pattern recognition receptor</td>
</tr>
<tr>
<td valign="top" align="left">DAI</td>
<td valign="top" align="left">DNA-dependent activator of interferon-regulatory factors</td>
</tr>
<tr>
<td valign="top" align="left">cGAS</td>
<td valign="top" align="left">cyclic GMP-AMP synthase</td>
</tr>
<tr>
<td valign="top" align="left">RIPK</td>
<td valign="top" align="left">receptor-interacting protein kinase</td>
</tr>
<tr>
<td valign="top" align="left">MLKL</td>
<td valign="top" align="left">mixed lineage kinase domain-like pseudokinase</td>
</tr>
<tr>
<td valign="top" align="left">NNSCC</td>
<td valign="top" align="left">head and neck squamous cell carcinoma</td>
</tr>
<tr>
<td valign="top" align="left">HCC</td>
<td valign="top" align="left">hepatocellular carcinoma</td>
</tr>
<tr>
<td valign="top" align="left">ROS</td>
<td valign="top" align="left">reactive oxygen species</td>
</tr>
<tr>
<td valign="top" align="left">GSH</td>
<td valign="top" align="left">glutathione</td>
</tr>
<tr>
<td valign="top" align="left">SLC7A11</td>
<td valign="top" align="left">solute carrier family 7 member 11</td>
</tr>
<tr>
<td valign="top" align="left">GPX4</td>
<td valign="top" align="left">glutathione peroxidase 4</td>
</tr>
<tr>
<td valign="top" align="left">RCC</td>
<td valign="top" align="left">renal cell carcinoma</td>
</tr>
<tr>
<td valign="top" align="left">NADPH</td>
<td valign="top" align="left">nicotinamide adenine dinucleotide phosphate</td>
</tr>
<tr>
<td valign="top" align="left">Cu</td>
<td valign="top" align="left">Copper</td>
</tr>
<tr>
<td valign="top" align="left">TCA</td>
<td valign="top" align="left">tricarboxylic acid</td>
</tr>
<tr>
<td valign="top" align="left">DLAT</td>
<td valign="top" align="left">dihydrolipoamide S-acetyltransferase</td>
</tr>
<tr>
<td valign="top" align="left">FDX1</td>
<td valign="top" align="left">ferredoxin 1</td>
</tr>
<tr>
<td valign="top" align="left">LIAS</td>
<td valign="top" align="left">lipoyl synthase</td>
</tr>
<tr>
<td valign="top" align="left">TTM</td>
<td valign="top" align="left">tetrathiomolybdate</td>
</tr>
<tr>
<td valign="top" align="left">ER</td>
<td valign="top" align="left">endoplasmic reticulum</td>
</tr>
<tr>
<td valign="top" align="left">NSCLC</td>
<td valign="top" align="left">non-small-cell lung cancer</td>
</tr>
<tr>
<td valign="top" align="left">IGFIR</td>
<td valign="top" align="left">insulin-like growth factor I receptor</td>
</tr>
<tr>
<td valign="top" align="left">PERK</td>
<td valign="top" align="left">pancreatic ER kinase (PKR)-like ER kinase</td>
</tr>
<tr>
<td valign="top" align="left">eIF2&#x3b1;</td>
<td valign="top" align="left">eukaryotic translation initiation factor 2&#x3b1;</td>
</tr>
<tr>
<td valign="top" align="left">ATF4</td>
<td valign="top" align="left">activating transcription factor 4</td>
</tr>
<tr>
<td valign="top" align="left">IDO</td>
<td valign="top" align="left">indoleamine 2,3-dioxygenase</td>
</tr>
<tr>
<td valign="top" align="left">PARP1</td>
<td valign="top" align="left">poly (ADP-ribose) polymerase 1</td>
</tr>
<tr>
<td valign="top" align="left">AIF</td>
<td valign="top" align="left">apoptosis-inducing factor</td>
</tr>
<tr>
<td valign="top" align="left">MIF</td>
<td valign="top" align="left">macrophage migration inhibitory factor</td>
</tr>
<tr>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">oral squamous cell carcinoma</td>
</tr>
<tr>
<td valign="top" align="left">AML</td>
<td valign="top" align="left">acute myeloid leukemia</td>
</tr>
<tr>
<td valign="top" align="left">PDAC</td>
<td valign="top" align="left">pancreatic ductal adenocarcinoma</td>
</tr>
<tr>
<td valign="top" align="left">ATP6V0D1</td>
<td valign="top" align="left">ATPase H+ transporting V0 subunit D1</td>
</tr>
<tr>
<td valign="top" align="left">STAT3</td>
<td valign="top" align="left">signal transducer and activator of transcription 3</td>
</tr>
<tr>
<td valign="top" align="left">V-ATPase</td>
<td valign="top" align="left">vacuolar ATPaseCA9: carbonic anhydrase 9</td>
</tr>
<tr>
<td valign="top" align="left">FANCD2</td>
<td valign="top" align="left">FA complementation group D2</td>
</tr>
<tr>
<td valign="top" align="left">ACSS2</td>
<td valign="top" align="left">acyl-CoA synthetase short-chain family member 2</td>
</tr>
<tr>
<td valign="top" align="left">CQ</td>
<td valign="top" align="left">chloroquine</td>
</tr>
<tr>
<td valign="top" align="left">CAR</td>
<td valign="top" align="left">chimeric antigen receptor</td>
</tr>
<tr>
<td valign="top" align="left">GSDM</td>
<td valign="top" align="left">gasdermin</td>
</tr>
<tr>
<td valign="top" align="left">NLR</td>
<td valign="top" align="left">NOD-like receptor</td>
</tr>
<tr>
<td valign="top" align="left">CDK</td>
<td valign="top" align="left">cyclin-dependent kinase</td>
</tr>
<tr>
<td valign="top" align="left">OSCC</td>
<td valign="top" align="left">oral squamous cell carcinoma</td>
</tr>
<tr>
<td valign="top" align="left">Gzm</td>
<td valign="top" align="left">granzyme</td>
</tr>
<tr>
<td valign="top" align="left">ZBP1</td>
<td valign="top" align="left">Z-form nucleic acid binding protein 1</td>
</tr>
<tr>
<td valign="top" align="left">RIG-I</td>
<td valign="top" align="left">retinoic acid inducible gene I</td>
</tr>
<tr>
<td valign="top" align="left">USP18</td>
<td valign="top" align="left">ubiquitin-specific protease 18</td>
</tr>
<tr>
<td valign="top" align="left">ISG</td>
<td valign="top" align="left">IFN-stimulated gene</td>
</tr>
<tr>
<td valign="top" align="left">LMP</td>
<td valign="top" align="left">lysosomal membrane permeabilization</td>
</tr>
<tr>
<td valign="top" align="left">NAC</td>
<td valign="top" align="left">N-acetylcysteine</td>
</tr>
</tbody>
</table>
</table-wrap>
</glossary>
</back>
</article>